



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07H 19/06, 19/067, 19/073 C07H 19/16, 19/167, 19/167 19/173		A1	(11) International Publication Number: WO 92/06102
			(43) International Publication Date: 16 April 1992 (16.04.92)
(21) International Application Number: PCT/SE91/00653		(74) Agents: LARFELDT, Helene et al.; Bergenstråhle & Lindvall AB, Box 17704, S-118 93 Stockholm (SE).	
(22) International Filing Date: 27 September 1991 (27.09.91)			
(30) Priority data: 9003151-9 2 October 1990 (02.10.90) SE		(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), CS, DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), GR (European patent), HU, IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent), SU*, US.	
(71) Applicant (for all designated States except US): MEDIVIR AB [SE/SE]; Lunastigen 7, S-141 44 Huddinge (SE).		Published With international search report.	
(72) Inventors; and			
(75) Inventors/Applicants (for US only): CLASSON, Björn, Olof [SE/SE]; Torsgränd 7, S-113 21 Stockholm (SE). SAMUELSSON, Bengt, Bertil [SE/SE]; Västra Ebbagårdsvägen 10, S-439 00 Cala (SE). KVARNSTROM, Ingemar, Sven-Anders [SE/SE]; Bygdegatan 212, S-583 31 Linköping (SE). SVANSSON, Lars, Göran [SE/SE]; SVENSSON, Stefan, Carl, Tore [SE/SE]; Rydsvägen 172B, S-582 48 Linköping (SE).			

(54) Title: NUCLEOSIDE DERIVATIVES



(1A)



(1B)

(57) Abstract

Novel antiviral compounds of formulae (1A) and (1B), wherein X and R¹-R⁴ are as stated in claim 1 in the form of an α- or β-anomer or a mixture thereof, and pharmaceutically acceptable salts thereof are disclosed, as well as a new method for preparation thereof. Said compounds can be used for treatment of infections caused by viruses requiring reverse transcriptase for replication, such as HIV and hepatitis B virus.

+ DESIGNATIONS OF "SU"

Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union. .

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU*	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

NUCLEOSIDE DERIVATIVES

Field of the invention

The present invention relates to novel chemical compounds and pharmaceutically acceptable salts thereof which can be used in therapy for therapeutic and prophylactic treatment of the acquired immuno deficiency syndrome (AIDS) and infections caused by viruses requiring reverse transcriptase for replication, such as human immuno deficiency viruses and hepatitis B virus, and also for treatment of other virus diseases, such as those of herpes viruses, diseases which include both common infections and neoplastic diseases, i.e. cancer.

Background of the invention

The effects of viruses on bodily functions is the end result of changes occurring at the cellular and subcellular levels. The pathogenic changes at the cellular level are different for different combinations of viruses and host cells. While some viruses cause a general destruction (killing) of certain cells, other may transform cells into a neoplastic state.

Important common viral infections are herpes dermatitis (including herpes labialis), herpes keratitis, herpes genitalis, herpes zoster, herpes encephalitis, infectious mononucleosis and cytomegalovirus infections all of which are caused by viruses belonging to the herpes virus group. Other important viral diseases are influenza A and B which are caused by influenza A and B virus, respectively. Another important common viral disease is viral hepatitis and especially hepatitis B virus infections are widely spread. Effective and selective antiviral agents are needed for treatment of these diseases as well as for other diseases caused by viruses.

Several different viruses of both DNA and RNA type have been shown to cause tumors in animals. The effect of cancerogenic chemicals can on animals result in activation of latent tumor viruses. It is possible that tumor viruses are involved in human tumors. The most likely human cases known today are leukemias, sarcomas, breast carcinomas, Burkitt lymph mas, nasopharyngeal carcinomas and cervical cancers where RNA tumor viruses and herpes viruses are involved. This makes the search for selective

inhibitors of tumorigenic viruses and their functions an important undertaking in the efforts to treat cancer.

In the late seventies a new disease was reported, which subsequently was referred to as Acquired Immuno Deficiency Syndrome (AIDS). It is now generally accepted that a retrovirus referred to as HIV (Human Immunodeficiency Virus), formerly known as Human T-cell Lymphotropic Virus (HTLV-III) or Lymphadenopathy Associated Virus (LAV) plays an essential role in the etiology of AIDS. Different types of HIV have been found, such as HIV-1 and HIV-2 and more are likely to be isolated.

AIDS is characterized by a profound immunodeficiency due to low numbers of a subset of lymphocyte-T-helper cells, which are one target for HIV infection. The profound immunodeficiency in AIDS patients makes these patients highly susceptible to a variety of opportunistic infections of bacterial, fungal, protozoal or viral etiology. The etiological agents among viral opportunistic infections are often found in the herpes virus group, i.e. herpes simplex virus (HSV), Varicella Zoster virus (VZV), Epstein-Barr virus (EBV) and, especially, cytomegalovirus (CMV). Other retroviruses affecting humans are HTLV-I and II and examples of retroviruses affecting animals are feline leukemia virus and equine infectious anaemia virus. Human diseases such as multiple sclerosis, psoriasis, tropical spastic paresis and Kawasaki disease have also been reported to be associated with retrovirus infections.

Hepatitis B virus infections cause severe disease such as acute hepatitis, chronic hepatitis, fulminant hepatitis in a considerable number of persons. It is estimated that there are 200 million patients with chronic hepatitis B infection in the world. A considerable number of the chronic cases progress to liver cirrosis and liver tumours. In some cases the hepatitis infections also take a rapid and severe course as in fulminant B hepatitis with about 90% mortality. At present there is no known effective treatment against hepatitis B infections. The replication of hepatitis B virus is similar to that of retrovirus and it contains the same essential viral reverse transcriptase activity.

General outline of the invention

A great number of nucleoside analogues exhibit several antimetabolic activities. They do so by substituting for or competing with the naturally occurring nucleosides. Recently some nucleoside analogues have been described, which inhibit in cell culture the multiplication of human immuno deficiency virus (HIV, also called HTLV-III, LAV) the causative agent of AIDS and AIDS-related complex (ARC). The nucleoside analogues described which inhibit HIV multiplication all have the β -D-furanosyl configuration.


We have now found that activities for inhibition of HIV multiplication are exhibited by nucleoside analogues in which the 2'-hydroxyl or 3'-hydroxyl is substituted for by a methyl or hydroxymethylene group or another methylene derivative thereof. The furanosyl moiety may have a D-configuration or L-configuration.

Prior art

Some of the compounds and intermediates of the invention have been described previously.

J. Med. Chem. Vol 22, 1979, 518-525 describes the synthesis of methyl 2,3-dideoxy-3-C-(hydroxymethyl)- β -D-erythropentofuranoside as well as the corresponding dibenzyl- and benzoyl derivative. The chloro derivative 5-O-benzoyl-3-C-[(benzoyloxy)methyl]-2,3-dideoxy-D-erythro-pentafuranosyl chloride was coupled with 2-acetamido-6-chloropurine. The product was processed further to give the two anomers of 2-amino-9-[2,3-dideoxy-3-C-3-(hydroxymethyl)-D-erythro-pentofuranosyl]-9H-purine-6(1H)-thione which were tested for antitumor activity. The synthesis of 2',3'-dideoxy-3'(R)-hydroxymethyl uridine has been described in Nucleosides & Nucleotides 1 (1982) 263-273. Uridine was converted to 1-(3-amino-2,3-dideoxy- β -D-glucopyranosyl)uracil via a multistage sequence, which was further reacted via ring contraction, epimerization and reduction to give 2',3'-dideoxy-3'(R)-hydroxymethyl uridine.


α -Anomer compounds of the formula




wherein X is O, S or CH₂; Y is OH or NH₂ and R⁵ is H, CH₃, CH₂CH₃, CH₂CH₂CH₃, CH(CH₃)₂, CH=CH₂, C≡CH or CH=CH-CH₃, and their β -anomers are described in the International Patent Application No. PCT/SE88/00169, (publication No. WO 88/08001).

Disclosure of the invention

The present invention relates to new compounds of the formula 1A OR 1B




1A




1B

wherein X is O, S, SO, SO₂ or CH₂; R¹ is OH, OPO(OH)₂, OPO(OH)-O-PO(OH)₂, OPO(OH)-O-PO(OH)-O-PO(OH)₂ or (CH₂)_nOCH₂PO(OH)₂ wherein n is 0-2; R² is H and R³ is CH₃, CH₂OH, CH₂OCH₃, CH₂SH, CH₂F or CH₂N₃; or R³ is H and R² is CH₃, CH₂OH, CH₂OCH₃, CH₂SH, CH₂F or CH₂N₃;



or




wherein Y is OH, NH₂ and R⁵ is CH=CH₂, C≡CH, CH=CH-CH₃, -C≡CH₃, thien-2-yl, thien-3-yl, H, CH₃, C₂H₅, n-C₃H₇ or i-C₃H₇;

R₆ and R₇ are the same or different and are H, F, Cl, OH, NH₂


or SH;

and pharmaceutically acceptable salts thereof.

In formula 1A the sugar has either the α -D- or the β -D-configuration.




1Ab β -D-configuration




1Aa α -D-configuration

In formula 1B the sugar has either the α -L- or the β -L-configuration.



1Ba α -L-configuration



1Bb β -L-configuration

Said compounds have been found to inhibit the multiplication of human immunodeficiency virus (HIV).

The invention consequently also refers to the compounds of the formulas 1A and 1B for use in therapy. The compounds of the formulas 1A and 1B are useful as therapeutic and/or prophylactic agents in the control and treatment of HIV virus infections in man. In a more general aspect, the compounds of the formulas 1A and 1B are useful as therapeutic and/or prophylactic agents in the control and treatment of infections caused by retroviruses and hepatitis B virus in mammals and man.

All retroviruses, including HIV, require the enzyme reverse transcriptase for replication.

Hepatitis B virus (HBV) is a DNA virus with a unique circular double-stranded DNA genome which is partly single-stranded. It contains a specific DNA polymerase required for viral replication. This DNA polymerase also acts as a

reverse transcriptase during the replication of HBV DNA via an RNA intermediate.

Other possible uses of the compounds of formulas 1A and 1B are as antimetabolic and antineoplastic compounds and compounds for treatment of other viruses.

One possible use for the compounds of the formulas 1A and 1B is in the treatment of herpes virus infection. Among the herpes viruses may be mentioned herpes simplex type 1 and 2, varicella (herpes zoster), virus causing infectious mononucleosis (i.e. Epstein-Barr virus), cytomegalovirus and human herpes virus type 6. Important diseases caused by herpes viruses are herpes dermatitis (including herpes labialis), herpes genitalis, herpes keratitis, herpes encephalitis and herpes zoster.

Another possible area of use for the compounds of the present invention is in the treatment of cancer and tumors, particularly those caused by viruses. This effect may be obtained in different ways, i.e. by inhibiting the spread of viruses from transformed cells to other normal cells and by arresting the growth of virus-transformed cells.

Another possible area of use for the compounds of the present invention is in the treatment of parasitic infections. Parasites usually have a specific enzyme activities for nucleoside metabolism making them amenable for therapy by nucleoside analogs. Among the parasites may be mentioned the Schistosoma, the Dipetalonema, the Trypanosoma, the Leishmania, the Trichomonas Emerea, the Plasmodium and the Toxoplasma families. In this regard, an important member of the Protozoa is Pneumocystis carinii, causing severe opportunistic infection in AIDS patients.

The invention furthermore provides:

A pharmaceutical composition comprising a compound of the formulas 1A and 1B as an active ingredient and a pharmaceutically acceptable carrier, including liposomes; and

A method for therapeutic and/or prophylactic treatment of virus infections in an animal or human host in need of treatment comprising administering an effective amount of a compound of the formulas 1A and 1B.


It is a preferred aspect of the invention to treat

infections caused by viruses requiring reverse transcriptase for replication, including human immuno deficiency viruses and hepatitis B virus.

The invention also relates to the use of a compound of the formulas 1A and 1B for the manufacture of a medicament for therapeutic and/or prophylactic treatment of the acquired immuno deficiency syndrome and infections caused by viruses requiring reverse transcriptase for replication.



Preferably they can be used for the treatment of infections caused by HIV viruses or hepatitis B virus.

The following compounds of formulas 1A are particularly useful in medical therapy.



1Ab

wherein X is O, S and CH₂; R¹ is OH; R² is H and R³ is CH₂OH; R³ is H and R² is CH₂OH;



Y is NH₂ and R⁵ is H; Y is OH and R⁵ is H, CH₃, C≡CH, CH = CH-CH₃; R⁶ is NH₂ and R⁷ is H, OH, SH or NH₂; R⁶ is H and R⁷ is OH, SH or NH₂; R⁶ is F or Cl and R⁷ is OH, SH or NH₂; R⁶ is OH and R⁷ is OH.

Examples of pharmaceutically acceptable salts of the compounds of formulas 1A and 1B include base salts, e.g. derived from an appropriate base, such as alkali metal (e.g. sodium, potassium, alkaline earth metal, e.g. magnesium) salts,

ammonium and tetraalkylammonium. Physiologically acceptable acid salts include salts of organic carboxylic acids such as acetic, lactic, gluconic, citric, tartaric, maleic, malic, pantothenic, isethionic, oxalic, lactobionic and succinic acids; organic sulfonic acids such as methanesulfonic, ethanesulfonic, benzenesulfonic, p-chlorobenzenesulfonic and p-toluenesulfonic acids and inorganic acids such as hydrochloric, hydroiodic, sulfuric, phosphoric and sulfamic acids.

Mono-, di- and triphosphate esters of the compounds are also included in the invention. Physiologically acceptable counterions of the phosphate groups include inorganic and organic counterions. Inorganic counterions are for example ammonium, sodium, potassium, lithium, magnesium and calcium. Organic counterions are derived from non-toxic bases, such as primary, secondary and tertiary amines, including naturally occurring amines. Examples of such amines are diethylamine, triethylamine, isopropylamine, ethanolamine, morpholine, 2-diethylaminoethanol, glucosamine, N-methylglucamine, piperazine and dicyclohexylamine.

In clinical practice the nucleoside analogues of the formula I will normally be administered orally, by injection or by infusion in the form of a pharmaceutical preparation comprising the active ingredient in the form of the original compound or optionally in the form of a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier which may be a solid, semi-solid or liquid diluent or an ingestible capsule. The compound may also be used without carrier material. As examples of pharmaceutical preparations may be mentioned tablets, dragées, capsules, granulates, suspensions, elixirs, syrups, solutions, liposomes etc. Usually the active substance will comprise between 0.05 and 20 % for preparations intended for injection and between 10 and 90 % for preparations intended for oral administration.

In the treatment of patients suffering from retrovirus, especially HIV, or hepatitis B virus infections, it will be preferred to administer the compounds by any suitable route including the oral, parenteral, rectal, nasal, topical and vaginal route. The parenteral route includes subcutaneous, intramuscular, intravenous and sublingual administration. The

topical route includes buccal and sublingual administration. The dosage at which the active ingredients are administered may vary within a wide range and will depend on various factors such as the severity of the infection, the age of the patient etc., and may have to be individually adjusted. As a possible range for the amount of the compounds of the invention or a physiologically acceptable salt thereof to be administered per day may be mentioned from about 10 mg to about 10000 mg, preferentially 50 - 500 mg for intravenous administration and preferentially 50 - 3000 mg for oral administration.

Compounds of the formulas 1A and 1B can cooperate synergistically or additively with a wide range of other therapeutic agents, thereby enhancing the therapeutic potential of both agents without adding the toxic effects, thus increasing the therapeutic ratio.

Therefore, a compound of formulas 1A and 1B or a pharmaceutically acceptable derivative thereof can be used in combination therapy, wherein the two active agents are present in a ratio resulting in an optimal therapeutic ratio. This can be provided either by a synergistic effect against the viral infection and/or by a decrease in toxicity while maintaining a therapeutic effect which is additive or synergistic.

The optimal therapeutic ratio is observed when the two agents are present in a ratio of 500:1 to 1:500, preferably 100:1 to 1:100, particularly 20:1 to 1:20 and especially 10:1 to 1:10.

Said combination may conveniently be administered together, for example, in a unitary pharmaceutical formulation, or separately for example as a combination of tablets and injections administered at the same time or at different times, in order to achieve the required therapeutic effect.

The compounds of the formulas 1A and 1B are potentiated by interferons, other antiviral agents such as foscarnet, AZT, fluorothymidine, dideoxyinosine, dideoxydihydrothymidine, 9-[4-hydroxy-(2-hydroxymethyl)butyl]guanine, acyclovir, HIV protease inhibitors, immunomodulators, interferon inducers and growth factors.

Particularly preferred types of interferon are α , β and γ interferon inducers.

Other combinations suitable for use according to the present

invention include those wherein the second agent is, for example, interleukin II, foscarnet esters, inhibitors of HIV protease such as pepstatin, steroids, medications such as levamisol or thymosin to increase lymphocyte numbers and/or function as appropriate, or G-CSF and other factors regulating cell functions.

Methods of preparation


The compounds of the invention may be prepared as outlined below, however, the invention is not limited to these methods. The compounds may also be prepared by processes described in the known art.

The synthesis of 1A where R^1 is OH, R^2 is H, R^3 is CH_2OH and R^4 is uracil-1-yl has been previously described in Nucleosides and Nucleotides, vol 1, 1982, 263-273. This derivative, suitably protected can be converted to other nucleoside derivatives by processes known in the art such as transglycosylation with suitably derivatized purine or pyrimidine bases or by chemical transformations of uracil.


The synthesis of methyl 2,3-dideoxy-3-C-(hydroxymethyl)- β -D-erythropentafuranoside and methyl 5-O-benzoyl-3-C-[(benzoyloxy)methyl]-2,3-dideoxy- β -D-erythro-pentofuranoside, starting from D-glucose, is described in J. Med. Chem., vol. 22, 1979, 518-525.

This latter compound was converted to 5-O-benzoyl-3-C-[(benzoyloxy)methyl]-2,3-dideoxy-D-erythro-pentofuranosyl chloride which was glycosylated with silylated 2-acetamido-6-chloropurine. The carbohydrate part of 1A can also be prepared from a protected 2,3-dideoxy-D-glycero-pent-2-enono-1,4-lact n through a 1,4-Michael type addition with an appropriate carbon nucleophile in an analogous manner as described in Carbohydr. Res. Vol. 183, 1988, 261-275 and J. Org. Chem., Vol. 53, 1988, 4780-4786.

A compound of the formula




wherein X, R¹, R², R³ and R⁴ are as defined in claim 1 can be prepared by condensing a glycoside as comprised in the formula to the N-1 position of a pyrimidine derivative or to the N-9 position of a purine derivative.




wherein Z is Cl, Br, J, acyloxy or alkoxy, and R¹, R², and R³ are R¹, R² and R³ respectively, as defined above or with the proviso that when R¹ or R² is OH then O must have a protecting group, R⁴' is R⁴ as defined above, having a silyl, acyl or alkyl protecting group

A compound of the formula




wherein X, R, R² and R³ are as defined in claim 1, can in the same way be prepared by condensing a glycoside as comprised in the formula to the N-1 position of a pyrimidine derivative or to the N-9 position of a purine derivative




wherein Z is Cl, Br, J, acyloxy or alkyloxy and R¹, R² and R³ are R, R² and R³ respectively as defined above or with the proviso that when R¹ or R² is OH must have a protecting group, R⁴ is R⁴ as defined above, having a silyl, acyl or alkyl protecting group.

According to a new method the compounds of the formula



wherein X, R¹, R² and R³ are as defined in claim 1 and Z is Cl, Br, J, acyloxy or alkoxy, can be prepared by reacting a protected butan-1,4-diol-2,3 epoxide with a nucleophile containing 3 or 4 carbon atoms with a double bond, followed by transforming the double bond and ring closure.

Compounds of the type 1A can thus be synthesized as outlined below in Scheme 1 or as in Scheme 2-4.




Scheme 1

This method is particularly useful, since by employing an epoxide with the chirality enantiomeric to that of 1, the L-sugars of the formula 1B are also synthesized. When R^8 is H, compounds with the different functionalities of R^3 are selectively prepared.

By analogous procedures the compounds wherein X is S are prepared. S may then be oxidized to SO and SO₂.

Compounds wherein X is CH₂ can be prepared as follows



Scheme 2

The chiral epoxide **1** [(2*S*,3*R*)-3-[[[(4-bromobenzyl)oxy]-methyl]oxirane-2-methanol] where R^9 is *p*-bromobenzyl and R^8 is hydrogen can be prepared as described in J. Org. Chem. Vol. 52, 1987, 2596-2598. R^9 and/or R^8 may be any base stable protecting group such as benzyl or alkyl or a silyl protecting groups. Epoxide **1** can be treated with allyl magnesium bromide or an allyl anion equivalent to give a mixture of **2** and **3** which are separated by conventional techniques such as chromatography or crystallization. In the case where R^8 is hydrogen the free hydroxyl in **2** is at this stage preferably protected with an acyl group, preferably benzoyl. Oxidative cleavage of the double bond and treatment of the product with anhydrous methanol containing a catalytic amount of acid gives **4**.


Compound **4** may be coupled to silylated purines or pyrimidines using acid catalysis to give the nucleoside derivative as an α - and β -mixture. In **4**, when R^9 and R^8 are not both benzoyl, **4** is preferably converted to this derivative by conventional deblocking and blocking procedures. The α - and β -anomeric mixture of nucleosides is preferably deprotected after which the α - and β -anomers are separated by conventional techniques such as chromatography or crystallization, to give **1A**.

as defined earlier in which R^1 and R^3 are hydroxyl and hydroxymethyl respectively.

Compounds of the type 1B are prepared entirely analogously by starting with an epoxide corresponding to 1 but having the opposite chirality.


Compounds wherein X is CH_2 are prepared from 7 (Chem. Pharm. Bull. 1988, 36, 15) by protecting the ketone as a ketal and reducing the esters to ethers using lithium aluminium hydride and hydrolyzing the ketal to give 8. Reduction of the ketone gave 9 which was condensed with a suitable purine derivative. Deprotection gave 1A. Compounds of the type 1B where X is CH_2 were synthesized in the same way.

Compounds of the type 1A wherein X is O and R^2 is CH_2OH , CH_2F or CH_2N_3 are prepared from (S)-4-(*tert.*-butyldiphenylsilyloxy)-methyl- γ -butyrolactone(11) by acylation with ethyl formate and reduction with sodium borohydride and acylation to give 12 after separation using silica gel column chromatography. Reduction with dialkylaluminium hydride followed by acylation gave 13. This compound was glycosylated with suitable nucleoside base derivatives.



R^{10} = *tert.*-butyl-diphenyl-silylchloride

Scheme 3



Bz = benzoyl Bn = benzyl T = thymidine C = cytosine

Scheme 4

Compounds of the type 1A wherein X = S are prepared from **14** by treatment with benzyl mercaptane and stannic chloride to give **15**. Ring closure of **15** using triphenylphosphine and triiodoimidazole afforded **16**. A portion of compound **16** was condensed with silylated thymine. The rest of compound **16** was treated with mercuric acetate to give **17** which was condensed with silylated cytosine.

The following illustrates the principle and the adaption of the invention, however, without being limited thereof. Temperature is given in degrees Celsius. Concentrations were performed under diminished pressure (1-2 kPa) at a bath

temperature not exceeding 40°C. NMR spectra were measured with a JEOL GX-270 or FX-100 instrument, using D₂O or CDCl₃ solutions. TMS (for CDCl₃) and TSP or dioxane (for D₂O) were used as internal standards. The shifts are reported in ppm. UV absorption spectra were recorded with a Perkin-Elmer Lambda 5 spectrophotometer. TLC were performed on Merck precoated 60 F-254 plates. Spots were visualized by UV light and/or charring with 8% sulfuric acid. Column chromatography was performed using silica gel 60 (0.040-0.063 MM, Merck). HPLC was performed on a prepacked steel column (250 x 25 mm) using Polygosil 60-7, C-18 (Macherey-Nagel). Organic phases were dried over anhydrous magnesium sulphate. Optical rotations were determined with a Perkin-Elmer 141 polarimeter.

This invention can be illustrated by the following examples:

Example 1

1-[2',3'-Dideoxy-3'-C-(hydroxymethyl)-β-D-erythro-pentofuranosyl]-cytosine.

A suspension of cytosine (120 mg, 1.08 mmol) and a small crystal of (NH₄)₂SO₄ in hexamethyldisilazane (2 ml) and trimethylchlorosilane (0.2 ml) was refluxed until a clear solution was obtained. The solution was concentrated in vacuo and co-evaporated with dry xylene. The solid residue was dissolved in dry CH₂Cl₂ (2 ml) under nitrogen and methyl-5-O-benzoyl-3-[(benzoyloxy)methyl]-2,3-dideoxy-D-erythro-pentofuranoside (170 mg, 0.46 mmol) was added followed by the addition of a t-butyl-dimethylsilyl-triflate (0.22 ml, 0.96 mmol). After 24 h at room temperature the reaction was quenched by the addition of aqueous NaHCO₃ (sat.) and the resulting mixture was stirred for 30 minutes. The solution was diluted with CH₂Cl₂ and washed with NaHCO₃ (sat.), dried, filtered and concentrated to give an anomeric mixture of the protected nucleoside. This mixture was treated with methanolic ammonia (20 ml, sat.) for 24 h at room temperature. After concentration, the residue was dissolved in water and extracted with CH₂Cl₂. The aqueous phase was concentrated to a small volume and was applied to a semi-preparative C-18 reversed phase chromatography column and eluted with water containing 2% methanol. First the α-isomer

was collected, followed by the β -isomer. The appropriate fractions were combined and evaporated to give 33 mg of the α -anomer (30%) and 27 mg of the β -anomer (24%). α -Anomer: $[\alpha]^{26}_D$: -54° (c 0.3, H₂O); UV (H₂O) λ_{\max} : 272 nm (ϵ 10894); ¹H-NMR (270 MHz, D₂O): 1.92 (m, $J_{2'a,2'b}$ = 13.5 Hz, $J_{2'a,3'}$ = 9 Hz, $J_{2'a,1'}$ = 6.5 Hz, 1H, H-2'a); 2.5 (m, 1H, H-3'); 2.7 (m, $J_{2'a,2'b}$ = 13.5 Hz, $J_{2'a,3'}$ = 8 Hz, $J_{2'a,1'}$ = 6 Hz, 1H H-2'b); 3.67, 3.69 (d and q, overlapping, $J_{6',3'}$ = 6.2 Hz, $J_{5'a,5'b}$ = 12.5 Hz, $J_{4',5'a}$ = 5.3 Hz, 3H, H-6' and H-5'a); 3.85 (q, $J_{5'a,5'b}$ = 12.5 Hz, $J_{4',5'b}$ = 3 Hz, 1H, H-5'b); 4.28 (m, $J_{3',4'}$ = 8 Hz, $J_{4',5'a}$ = 5.3 Hz, $J_{4',5'b}$ = 3 Hz, 1H, H-4'); 6.1 (d and q, overlapping, $J_{5,6}$ = 7.3 Hz, $J_{1',2'}$ = 6.5 Hz, 2H, H-5 and H-1'); 7.8 (d, $J_{5,6}$ = 7.3 Hz, 1H, H-6); ¹³C-NMR (25.05 MHz, D₂O): 36.4 (C-2'); 42.3 (C-3'); 62.7, 63.6 (C-5', C-6'); 84.4, 88.2 (C-1', C-4'); 96.6 (C-5); 141.9 (C-6); 158.1 (C-2); 166.8 (C-4). β -Anomer: $[\alpha]^{26}_D$: +64° (c 0.27, H₂O); UV (H₂O) λ_{\max} : 272 nm (ϵ 9208); ¹H-NMR (270 MHz, D₂O): 2.2-2.46 (m, 3H, H-2; H-3'); 3.68 (d, $J_{3',6'}$ = 5.5 Hz, 2H, H-6'); 3.76 (dd, $J_{4',5'a}$ = 5.5 Hz, $J_{5'a,5'b}$ = 12.5 Hz, 1H, H-5'a); 3.92 (dd, $J_{4',5'b}$ = 2.9 Hz, $J_{5'a,5'b}$ = 12.5 Hz, 1H, H-5'b); 4.01 (m, $J_{3',4'}$ = 8.1 Hz, $J_{5'a,4'}$ = 5.5 Hz, $J_{5'b,4'}$ = 2.9 Hz, 1H, H-4'); 6.05 (3, $J_{5,6}$ = 7.3 Hz, 1H, H-5); 6.11 (dd, $J_{1',2'a}$ = 7.0 Hz, $J_{1',2'b}$ = 4.0 Hz, 1H, H-1'); 7.91 (d, $J_{5,6}$ = 7.3 Hz, 1H, H-6); ¹³C-NMR (25.05 MHz, D₂O): 36.1 (C-2'); 40.8 (C-3'); 62.7, 63.1 (C-5', C-6'); 84.7, 87.1 (C-1', C-4'); 96.5 (C-5); 142.2 (C-6); 158.2 (C-2); 166.8 (C-4).

Example 2

9-[2',3'-Dideoxy-3'-C-(hydroxymethyl)- β -D-erythro-pentofuranosyl]-adenosine; and

Example 3

9-[2',3'-Dideoxy-3'-C-(hydroxymethyl)- α -D-erythro-pentofuranosyl]-adenosine.

6-chloro-purine (200 mg, 1.3 mmol) was condensed with methyl 5-O-benzoyl-3-[(benzoyloxy)methyl]-2,3-dideoxy-D-erythr-pentofuran side (280 mg, 0.76 mmol) following the same procedure as described in examples 1 and 2 but using acetonitrile was used instead of CH₂Cl₂ as solvent to give an anomeric mixture which after isolation was dissolved in

methanolic ammonia (5 ml) and heated at 100 in a sealed tube. After 20 h the solvent was removed and the residue dissolved in water and extracted with CH_2Cl_2 . The aqueous layer was concentrated to a small volume and was applied to a semi-preparative C-18 reversed phase chromatography column and eluted with water containing 8 % methanol. First the α -isomer was eluted, followed by the β -isomer. The appropriate fractions were combined and evaporated to give 20 mg of the α -anomer (Example 3) (10 %) and 40 mg of the β -anomer (Example 2) (20 %).

α -isomer: $[\alpha]^{26}_D$: +41° (c 0.23, H_2O); UV (H_2O) λ_{max} : 260 nm (e 12864); $^1\text{H-NMR}$ (270 MHz, D_2O): 2.45 (m, 1H, H-2'a); 2.6 (m, 1H, H-3') 2.82 (m, $J_{2'b,1'} = 6$ Hz, $J_{2'b,3'} = 7.8$ Hz, $J_{2'b,2'a} = 14$ Hz, 1H, H-2'b); 3.72 and 3.74 (q and d, overlapping, $J_{5'b,4'} = 5.5$ Hz, $J_{5'b,5'a} = 12.5$ Hz, $J_{6',3'} = 5.9$ Hz, 3H, H-5'b and H-6'); 3.86 (q, $J_{5'a,4'} = 2.9$ Hz, $J_{5'a,5'b} = 12.5$ Hz, 1 H, H-5'a); 4.31 (m, 1 H, H-4'); 6.35 (m, 1H, H-1'); 8.19 (s, 1H, H-2); 8.32 (s, 1H, H-8); $^{13}\text{C-NMR}$ (25.05 MHz, D_2O): 35.5 (C-2'); 42.3 (C-3'); 62.5, 63.3 (C-5', C-6'); 83.8, 85.3 (C-1', C-4'); 119.4 (C-5); 140.3 (C-8); 148.9 (C-4); 153.0 (C-2); 155.9 (C-6).

β -isomer: $[\alpha]^{26}_D$: -17 (c 0.27, H_2O); UV (H_2O) λ_{max} : 260 nm (e 10744); $^1\text{H-NMR}$ (270 MHz, D_2O): 2.5 (m, 1H, H-3'); 2.67 (m, 2H, H-2'); 3.69 (q, $J_{5'a,4'} = 5.1$ Hz, $J_{5'a,5'b} = 12.5$ Hz, 1H, H-5'a); 3.77 (d, $J_{6',3'} = 5.5$ Hz, 2H, H-6'); 3.87 (q, $J_{5'b,4'} = 2.9$ Hz, $J_{5'b,5'a} = 12.5$ Hz, 1H, H-5'b); 4.13 (m, 1H, H-4'); 6.34 (m, 1H, H-1'); 8.18 (s, 1H, H-2); 8.32 (s, 1H, H-8). $^{13}\text{C-NMR}$ (25.05, MHz D_2O): 35.7 (C-2'); 41.4 (C-3'); 62.8, 63.4 (C-5', C-6'); 85.0, 85.3 (C-1', C-4'); 119.2 (C-5); 140.5 (C-8); 148.7 (C-4); 153.0 (C-2); 155.8 (C-6).

Example 4

1-[2',3'-Dideoxy-3'-C-(hydroxymethyl)- β -D-erythro-pentofuranosyl]-thymine.

Thymine (150 mg, 1.19 mmol) was condensed with methyl 3-C-[(benzoyloxy)methyl]-5-O-p-bromobenzyl-2,3-dideoxy-D-erythro-pentofuran side (205 mg, 0.47 mmol) following the same procedure as described in Examples 1 and 2 to give an anomeric mixture of the protected nucleoside. The mixture was dissolved in ethanol containing NaHCO_3 (excess) and was hydrogenated over

Pd (10 % on carbon, 1 atm) for 3 hours. After workup the residue was further reacted with methanolic ammonia for 24 h. After concentration the residue was dissolved in water and extracted with CH_2Cl_2 . The aqueous layer was concentrated to a small volume and was subjected to semi-preparative C-18 reversed phase column chromatography and eluted with water containing 10 % methanol. First the α -isomer was eluted, followed by the β -isomer. The appropriate fractions were combined and evaporated to give 40 mg of the α -anomer (33%) and 41 mg of β -anomer (33%).

α -Isomer: $[\alpha]^{26}_D$: -3.6 (c 0.36, H_2O); UV (H_2O) λ_{max} : 268 nm (e 13756); $^1\text{H-NMR}$ (270 MHz, D_2O): 1.89 (d, $J = 1.1$ Hz, 3H, 5- CH_3); 1.96 (m, $J_{2'a,2'b} = 13.2$ Hz, $J_{2'a,3'} = 9.9$ Hz, $J_{2'a,1'} = 7.7$ Hz, 1H, H-2'a); 2.47 (m, 1H, H-3'); 2.6 (m, $J_{2'a,2'b} = 13.2$ Hz, $J_{2'b,3'} = 8.1$ Hz, $J_{2'b,1'} = 6.2$ Hz, 1H, H-2'b); 3.64 and 3.68 (d and q overlapping, $J_{5'a,4'} = 5.5$ Hz, $J_{5'a,5'b} = 12.1$ Hz, $J_{6',3'} = 6.1$ Hz, 3H, H-5'a, H-6'); 3.81 (q, $J_{5'b,4'} = 2.9$ Hz, $J_{5'b,5'a} = 12.1$ Hz, H-5'b); 4.24 (m, $J_{3',4'} = 8.4$ Hz, $J_{4',5'a} = 5.5$ Hz, $J_{4',5'b} = 2.9$ Hz, 1H, H-4); 6.11 (q, $J_{1',2'a} = 7.7$ Hz, $J_{1',2'b} = 6.2$ Hz, 1H, H-1'); 7.59 (d, $J = 1.1$ Hz, 1H, H-6); $^{13}\text{C-NMR}$ (25.05 MHz, D_2O): 12.5 (5- CH_3); 35.7 (C-2'); 42.7 (C-3'); 62.6, 63.5 (C-5', C-6'); 84.2, 87.3 (C-1', C-4'); 111.6 (C-5); 138.1 (C-6); 152.4 (C-2); 167.3 (C-4).

β -Isomer: $[\alpha]^{26}_D$: +17.8 (c 0.41, H_2O); UV (H_2O) λ_{max} : 268 nm (e 8516); $^1\text{H-NMR}$ (270 MHz, D_2O): 1.91 (s, 3H, 5- CH_3); 2.3 (m, 2H, H-2'); 2.5 (m, 1H, H-3'); 3.69 (d, $J_{3',6'} = 5.9$ Hz, 2H, H-6'); 3.76 (q, $J_{5'b,5'a} = 12.4$ Hz, $J_{5'b,4'} = 5.1$ Hz, 1H, H-5'b); 3.9 (q, $J_{5'a,5'b} = 12.4$ Hz, $J_{5'a,4'} = 2.9$ Hz, 1H, H-5'a); 3.99 (m, $J_{4',5'a} = 2.9$ Hz, $J_{4',5'b} = 5.1$ Hz, $J_{4',3'} = 8.1$ Hz, 1H, H-4); 6.14 (q, $J_{1',2'a} = 4.8$ Hz, $J_{1',2'b} = 6.6$ Hz, 1H, H-1'); 7.73 (d, $J = 1.1$ Hz, 1H, H-6). $^{13}\text{C-NMR}$ (25.05 MHz, D_2O): 12.5 (5- CH_3); 35.4 (C-2'); 40.9 (C-3'); 62.8, 62.9 (C-5', C-6'); 84.5, 86.1 (C-1', C-4'); 111.7 (C-5); 138.3 (C-6); 152.7 (C-2); 167.5 (C-4).

Analogously the corresponding nucleoside analogs of the formula 1B, having the L-configuration, were synthesized in examples 5-10. The synthetic strategy was identical to that one outlined in scheme 1 and described in the detail for the preparation of Examples 1 - 4 and their starting materials. For

Examples 5 - 10, the starting material corresponding to formula 1 of scheme 1 was:

(2R,3S)-3-[[(4-bromobenzyl)oxy]methyl]oxirane-2-methanol.

Example 5

1-[2',3'-Dideoxy-3'-C-(hydroxymethyl)- β -L-erythro-pentofuranosyl]-cytosine; and

Example 6

1-[2',3'-Dideoxy-3'-C-(hydroxymethyl)- α -L-erythro-pentofuranosyl]-cytosine.

The α -anomer had $[\alpha]_D^{22}$: +57.3° (c 0.61, H₂O); UV (H₂O) λ_{\max} : 273 nm (ϵ 7647); ¹H-NMR (270 MHz, D₂O): 1.92 (m, J_{2'a,2'b}=13.5 Hz, J_{2'a,3'}= 9 Hz, J_{2'a,1'}=6.5 Hz, 1H, H-2'a); 2.5 (m, 1H, H-3'); 2.7 (m, J_{2'a,2'b}= 13.5 Hz, J_{2'a,3'}= 8Hz, J_{2'a,1'}= 6 Hz, 1H H- 2'b); 3.67, 3.69 (d and dd, overlapping, J_{6',3'}= 6.2 Hz, J_{5'a,5'b}= 12.5 Hz, J_{4',5'a}= 5.3 Hz, 3H, H-6' and H-5'a); 3.85 (dd, J_{5'a,5'b}= 12.5 Hz, J_{4',5'b}= 3 Hz, 1H, H-5'b); 4.28 (m, J_{3',4'}= 8 Hz, J_{4',5'a}= 5.3 Hz, J_{4',5'b}= 3 Hz, 1H, H-4'); 6.1 (d and t, overlapping, J_{5,6}= 7.3 Hz, J_{1,2'}= 6.5 Hz, 2H, H-5 and H-1'); 7.8 (d, J_{5,6}= 7.3 Hz, 1H, H-6); ¹³C-NMR (25.05 MHz, D₂O): 36.4 (C-2'); 42.3 (C-3'); 62.7, 63.6 (C-5', C-6'); 84.4, 88.2 (C-1', C-4'); 96.6 (C-5); 141.9 (C-6); 158.1 (C-2); 166.8 (C-4). β -Anomer: $[\alpha]_D^{22}$: -76.3° (c 1.14 H₂O); UV (H₂O) λ_{\max} : 273 nm (ϵ 5333); ¹H-NMR (270 MHz, D₂O): 2.2-2.46 (m, 3H, H-2; H-3'); 3.68 (d, J_{3',6'}= 5.5 Hz, 2H, H-6'); 3.76 (dd, J_{4',5'a}= 5.5 Hz, J_{5'a,5'b}= 12.5 Hz, 1H, H-5'a); 3.92 (dd, J_{4',5'b}= 2.9 Hz, J_{5'a,5'b}= 12.5 Hz, 1H, H-5'b); 4.01 (m, J_{3',4'}= 8.1 Hz, J_{5'a,4'}= 5.5 Hz, J_{5'b,4'}= 2.9 Hz, 1H, H-4'); 6.05 (3, J_{5,6}= 7.3 Hz, 1H, H-5); 6.11 (dd, J_{1',2'a}= 7.0 Hz, J_{1',2'b}= 4.0 Hz, 1H, H-1'); 7.91 (d, J_{5,6}= 7.3 Hz, 1H, H- 6); ¹³C-NMR (25.05 MHz, D₂O): 36.1 (C-2'); 40.8 (C-3'); 62.7, 63.1 (C-5', C-6'); 84.7, 87.1 (C-1', C-4'); 96.5 (C-5); 142.2 (C-6); 158.2 (C-2); 166.8 (C-4).

Example 7

9-[2',3'-Dideoxy-3'-C-(hydroxymethyl)- β -L-erythro-pentofuranosyl]-adenosine; and

Example 8

9-[2',3'-Dideoxy-3'-C-(hydroxymethyl)- α -L-erythro-pentofuranosyl]-adenosine

The α -anomer: $[\alpha]_D^{22}$: -45.2° (c 0.37, H₂O); UV (H₂O) λ_{\max} : 260 nm (ϵ 10987); ¹H-NMR (270 MHz, D₂O): 2.45 (m, 1H, H-2'a); 2.6 (m, 1H, H-3'); 2.82 (m, $J_{2'b,1'} = 6$ Hz, $J_{2'b,3'} = 7.8$ Hz, $J_{2'b,2'a} = 14$ Hz, 1H, H-2'b); 3.72 and 3.74 (dd and d, overlapping, $J_{5'b,4'} = 5.5$ Hz, $J_{5'b,5'a} = 12.5$ Hz, $J_{6',3'} = 5.9$ Hz, 3H, H-5'b and H-6'); 3.86 (q, $J_{5'a,4'} = 2.9$ Hz, $J_{5'a,5'b} = 12.5$ Hz, 1H, H-5'a); 4.31 (m, 1H, H-4'); 6.35 (m, 1H, H-1'); 8.19 (s, 1H, H-2); 8.32 (s, 1H, H-8); ¹³C-NMR (25.05 MHz, D₂O): 35.5 (C-2'); 42.3 (C-3'); 62.5, 63.3 (C-5', C-6'); 83.8, 85.3 (C-1', C-4'); 119.4 (C-5); 140.3 (C-8); 148.9 (C-4); 153.0 (C-2); 155.9 (C-6).

The β -anomer: $[\alpha]_D^{22}$ $+22.5^\circ$ (c 0.44, H₂O); UV (H₂O) λ_{\max} : 260 nm (ϵ 11482); ¹H-NMR (270 MHz, D₂O): 2.5 (m, 1H, H-3'); 2.67 (m, 2H, H-2'); 3.69 (dd, $J_{5'a,4'} = 5.1$ Hz, $J_{5'a,5'b} = 12.5$ Hz, 1H, H-5'a); 3.77 (d, $J_{6',3'} = 5.5$ Hz, 2H, H-6'); 3.87 (dd, $J_{5'b,4'} = 2.9$ Hz, $J_{5'b,5'a} = 12.5$ Hz, 1H, H-5'b); 4.13 (m, 1H, H-4'); 6.34 (m, 1H, H-1'); 8.18 (s, 1H, H-2); 8.32 (s, 1H, H-8). ¹³C-NMR (25.05 MHz D₂O): 35.7 (C-2'); 41.4 (C-3'); 62.8, 63.4 (C-5' and C-6'); 85.0, 85.3 (C-1' and C-4'); 119.2 (C-5); 140.5 (C-8); 148.7 (C-4); 153.0 (C-2); 155.8 (C-6).

Example 9

1-[2',3'-Dideoxy-3'-C-(hydroxymethyl)- β -L-erythro-pentofuranosyl]-thymine and

Example 10

1-[2',3'-Dideoxy-3'-C-(hydroxymethyl)- α -L-erythro-pentofuranosyl]-thymine

The α -anomer had $[\alpha]_D^{22}$: $+8.3^\circ$ (c 0.48, H₂O); UV (H₂O) λ_{\max} : 268 nm (ϵ 7976); ¹H-NMR (270 MHz, D₂O): 1.89 (d, $J = 1.1$ Hz, 3H, 5-CH₃); 1.96 (m, $J_{2'a,2'b} = 13.2$ Hz, $J_{2'a,3'} = 9.9$ Hz, $J_{2'a,1'} = 7.7$ Hz, 1H, H-2'a); 2.47 (m, 1H, H-3'); 2.6 (m, $J_{2'a,2'b} = 13.2$ Hz, $J_{2'b,3'} = 8.1$ Hz, $J_{2'b,1'} = 6.2$ Hz, 1H H-2'b); 3.64, 3.68 (d and dd, overlapping, $J_{5',4'} = 5.5$ Hz, $J_{5'a,5'b} = 12.1$ Hz, $J_{6',3'} = 6.1$ Hz, 3H, H-6'a and H-6'); 3.81 (dd, $J_{5'b,5'a} = 2.9$ Hz, $J_{5'b,5'a} = 12.1$ Hz, H-5'b); 4.24 (m, $J_{3',4'} = 8.4$ Hz, $J_{4',5'a} = 5.5$ Hz, $J_{4',5'b} = 2.9$ Hz, 1H, H-4); 6.11 (dd, $J_{1',2'a} = 7.7$ Hz, $J_{1',2'b} =$

6.2 Hz, 1H, H-1); 7.59 (d, $J = 1.1$ Hz, 1H, H-6); ^{13}C -NMR (25.05 MHz, D_2O): 12.5 (5- CH_3) 35.7 (C-2'); 42.7, (C-3') 62.6, 63.5 (C-5' and C-6'); 84.2, 87.3 (C-1' and C-4'); 111.6 (C-5); 138.1 (C-6); 152.4 (C-2); 167.3 (C-4).

The β -anomer: $[\alpha]_D^{22}$: -21.2° (c 0.32 H_2O); λ_{max} : 268 nm (ϵ 8123); ^1H -NMR (270 MHz, D_2O): 1.91 (s, 3H, 5- CH_3);

2.3 (m, 2H, H-2'); 2.5 (m, = 1H, H-3'); 3.69 (d, $J_{3',6'} = 5.9$ Hz, 2H, H-6'), 3.76 (dd, $J_{5'b,5'a} = 12.4$ Hz, $J_{5'b,4} = 5.1$ Hz, 1H, H-5'b); 3.9 (dd, $J_{5'a,5'b} = 12.4$ Hz, $J_{5'a,4'} = 2.9$ Hz, 1H, H-5'a); = 3.99 (m, $J_{4',5'a} = 2.9$ Hz, ($J_{4',5'b} = 5.1$ Hz, $J_{4',3'} = 8.1$ Hz, 1H, H-4); 6.14 (dd, $J_{1',2'a} = 4.8$ Hz, $J_{1',2'b} = 6.6$ Hz, 1H, H-1); 7.73 (d, $J = 1.1$ Hz 1H, H-6). ^{13}C -NMR (25.05 MHz, D_2O): 12.5 (5- CH_3), 35.4 (C-2'); 40.9 (C-3'); 62.8, 62.9 (C-5' and C-6'); 84.5, 86.1 (C-1' and C-4'); 111.7 (C-5); 138.3 (C-6); 152.7 (C-2); 167.5 (C-4).

General procedure for the silylations used in Examples 11-16. A suspension consisting of the base (1 mmol) and a small crystal of ammonium sulfate in a mixture of hexamethyldisilazane (2 ml) and trimethylchlorosilane (0.2 ml) was refluxed until a clear solution was obtained. Volatile matters were evaporated off, and the residue was repeatedly coevaporated with added xylene.

EXAMPLE 11

1-[2',3'-Dideoxy-3'-C-(fluoromethyl)- α - and β -D-erythro-pentofuranosyl]-thymine.

Thymine (150 mg, 1.19 mmol) was silylated according to the general procedure and dissolved in dichloromethane (5 ml) under nitrogen. To this solution was added methyl 5-O-benzoyl-3-C-(fluoromethyl)-2,3-dideoxy-D-erythro-pentofuranoside (200 mg, 0.75 mmol) followed by tert-butyldimethylsilyl triflate (0.3 ml, 1.31 mmol). The solution was stirred for 24 hours at room temperature, after which the reaction was quenched by the addition of aqueous sodium hydrogen carbonate, stirred for 30 min, diluted with dichloromethane, washed with aqueous sodium hydrogen carbonate, dried, and concentrated to give an anomeric mixture of the protected nucleosides. The mixture was treated with methanolic ammonia (20 ml, saturated) for 24 h at room temperature. After concentration to dryness, the residue was

dissolved in water and washed with dichloromethane. The aqueous layer was concentrated to a small volume and the mixture was separated by column chromatography (ethyl acetate-methanol 20:1). The β -anomer was eluted first followed by the α -anomer. The appropriate fractions were combined and evaporated to give the title compounds, α (70 mg, 36 %) and β (54 mg, 28 %). α : $[\alpha]^{22}_D -13.1^\circ$ (c 0.82, H_2O); UV (H_2O) λ_{max} 268 nm (ϵ 9268); 1H NMR (270 MHz, D_2O) δ 2.92 (s- CH_3), 2.06 (H-2'a), 2.60-2.82 (m, H-2'b and H-3'), 3.68 (dd, H-5'a), 3.85 (dd, H-5'b), 4.38 (m, H-4), 4.46-4.75 (2 m, H-6'a-b), 6.15 (t, H-1'), 7.60 (d, H-6). Anal. Calcd. for $C_{11}H_{15}O_4N_2F$: C, 51.16; H, 5.85; N, 10.85. Found: C, 50.91; H, 5.78; N, 10.85. β : $[\alpha]^{22}_D +16.3^\circ$ (c 0.6, H_2O); UV (H_2O) λ_{max} 268 nm (ϵ 8880); 1H NMR (270 MHz, D_2O) δ 1.91 (d, s- CH_3), 2.3 (m, H-2'), 2.73 (m, H-3'), 3.78 (dd, H-5'a), 3.94 (dd, $J_{4',5'b} = 2.9$ Hz, H-5'b), 4.1 (m, H-4), 4.44-4.73 (2 m, H-6'a,b), 6.15 (dd, H-1'), 7.77 (d, $J = 1.1$ Hz, H-6). Anal. Calcd for $C_{11}H_{15}O_4N_2F$: C, 51.16; H, 5.85; N, 10.85. Found: C, 51.10; H, 5.76; N, 10.95.

EXAMPLE 12

1-[2',3'-Dideoxy-3'-C-(fluoromethyl)- α -and- β -D-erythro-pentofuranosyl]cytosine.

Cytosine (200 mg, 1.8 mmol) was silylated according to the general procedure and the synthesis was proceeded as described above to give the title compounds α (38 mg, 38 %) and β (26 mg, 26 %). α : $[\alpha]^{22}_D -53.7^\circ$ (c 0.94, H_2O); UV (H_2O) λ_{max} 272 nm (ϵ 7762); 1H NMR (270 MHz, D_2O) δ 1.98 (m, H-2'a), 2.58-2.80 (m, H-2'b and H-3'), 3.68 (H-5'a), 3.85 (dd, H-5'b), 4.37 (m, H-4), 4.39-4.72 (2 m, H-6'a,b), 6.04 (d, H-5), 6.12 (t, H-1'), 7.70 (d, H-6). Anal. Calcd. for $C_{10}H_{14}O_3N_3F$: C, 49.38; H, 5.80. Found: C; H. β : $[\alpha]^{22}_D +44.8^\circ$ (c 0.6, H_2O); UV (H_2O) λ_{max} 272 nm (ϵ 8515); 1H NMR (270 MHz, D_2O) δ 2.23 (m, H-2'a), 2.39 (m, $J_{2'b,3'} = 8.5$ Hz, H-2'b), 2.65 (m, H-3'), 3.77 (dd, H-5'a), 3.93 (dd, H-5'b), 4.11 (m, H-4), 4.43-4.73 (two m, H-6'a,b), 6.03 (d, H-5), 6.10 (dd, H-1'), 7.93 (d, H-6). Anal. Calcd. for $C_{10}H_{14}O_3N_3F$: C, 49.38; H, 5.80. Found: C; H.

EXAMPLE 13

9-[2',3'-Dideoxy-3'-C-(fluoromethyl)- α -and- β -D-erythro-pentofuranosyl]adenine. 6-Chloropurine (120 mg, 0.78 mmol) was silylated according to the general procedure and the synthesis was proceeded as described above to give the title compounds α (25 mg, 26 %) and β (37 mg, 39 %). α : $[\alpha]^{22}_D$ 35.2° (c 0.71, H₂O); UV (H₂O) λ_{max} 260 nm (ϵ 10239); ¹H NMR (270 MHz, D₂O) δ 2.5 (m, H-2'a), 2.70-2.95 (m, H-2'b and H-3'), 3.73 (dd, H-5'a), 3.88 (dd, H-5'b), 4.40 (m, H-4), 4.52-4.78 (2 m, $J_{3',6'b}$ = 10.0 Hz, H-6'a-b), 6.34 (t, H-1'), 8.15 (s, H-2), 8.29 (s, H-8). Anal. Calcd. for C₁₁H₁₄O₂N₅F: C, 49.43; H, 5.28. Found: C; H. β : $[\alpha]^{22}_D$ -24.3° (c 0.9, H₂O); UV (H₂O) λ_{max} 260 nm (ϵ 10364); ¹H NMR (270 MHz, D₂O) δ 2.47-2.48 (2 m, H-2'a,b), 2.95 (m, H-3'), 3.69 (dd, H-5'a), 3.87 (dd, H-5'b), 4.21 (m, H-4), 4.51-4.78 (2 m, H-6'a,b), 6.24 (dd, H-1'), 8.04 (s, H-2), 8.25 (s, H-8). Anal. Calcd. for C₁₁H₁₄O₂N₅F: C, 49.43; H, 5.28. Found: C,; H,.

EXAMPLE 14

1-[2',3'-Dideoxy-3'-C-(azidomethyl)- α -and- β -D-erythro-pentofuranosyl]-thymine.

Thymine (133 mg, 1.06 mmol) was silylated according to the general procedure and dissolved in dichloromethane (5 ml) under nitrogen. To this solution was added methyl 3-C-(azidomethyl)-5-O-(benzoyl)-2',3'-dideoxy-D-erythro-pentofuranoside (154 mg, 0.53 mmol) followed by tert-butyltrimethylsilyl triflate (0.25 ml, 1.09 mmol). The solution was stirred for 24 hours at room temperature, after which the reaction was quenched by the addition of aqueous sodium hydrogen carbonate, stirred for 30 min, diluted with dichloromethane, washed with aqueous sodium hydrogen carbonate, dried, and concentrated to give an anomeric mixture of the protected nucleosides. The mixture was treated with methanolic ammonia (20 ml, saturated) for 24 h at room temperature. After concentration to dryness, the residue was dissolved in water and washed with dichloromethane. The aqueous layer was concentrated to a small volume and freeze dried to give 110 mg (0.39 mmol, 74 %) of an anomeric mixture of the deblocked nucleosides. The mixture was dissolved in a mixture of N,N-dimethylformamide and imidazole (53 mg, 0.78 mmol) followed by the addition of tert-butyltrimethyl-

silyl chloride (70 mg, 0.46 mmol), and the solution was stirred for 3 h at room temperature. Water (1 ml) was added, and the mixture was stirred for 10 min, diluted with dichloromethane, washed with 1 M hydrogen chloride, saturated aqueous hydrogen carbonate, dried, and concentrated. The anomers were separated by column chromatography (hexane-ethyl acetate 1:1), the α -anomer was eluted first followed by the β -anomer. Each of the anomers was separately treated with tetrabutyl-ammonium fluoride (70 mg, 0.22 mmol) in tetrahydrofuran (2 ml) for 24 h, concentrated, the residue dissolved in water, and washed with dichloromethane. The aqueous layer was concentrated to a small volume and purified by HPLC (water-methanol, 80:20, v/v) to give the title compounds α (43 mg, 29 %) and β (44 mg, 30 %). α : $[\alpha]_D^{22} +3.1^\circ$ (c 1.45, H₂O); UV (H₂O) λ_{\max} 268 nm (ϵ 9155); ¹H NMR (270 MHz, D₂O) δ 1.92 (s, 5-CH₃), 2.02 (m, H-2'a), 2.50-2.74 (2 m, H-2'b and H-3'), 3.54 and 3.58 (2 dd, H-6'a,b), 3.67 (dd, H-5'a), 3.85 (dd, H-5'b), 4.25 (m, $J_{4,5a} = 5.1$ Hz, H-4), 6.12 (dd, H-1), 7.60 (d, H-6). Anal. Calcd. for C₁₁H₁₅O₄N₂F: C, 51.16; H, 5.85. Found: C.; H,. β $[\alpha]_D^{22} 12.5^\circ$ (c 0.96, H₂O); UV (H₂O) λ_{\max} 268 nm (ϵ 9434); ¹H NMR (270 MHz, D₂O) δ 1.91 (s, 5-CH₃), 2.34 (dd, H-2'), 2.59 (m, H-3'), 3.47-3.61 (2 dd, H-6'a,b), 3.78 (dd, H-5'a), 3.94 (dd, H-5'b), 3.98 (m, H-4), 6.1 (t, H-1), 7.76 (s, 1H, H-6). Anal. Calcd. for C₁₁H₁₅O₄N₃: C, 46.97; H, 5.38. Found: C.; H,.

EXAMPLE 15

1-[2',3'-Dideoxy-3'-C-(azidomethyl)- α -and- β -D-erythro-pentofuranosyl]cytosine.

Cytosine (250 mg, 2.25 mmol) was silylated according to the general procedure and the synthesis was proceeded as above to give the title compounds α (84 mg, 43 %) and β (45 mg, 23 %). α : $[\alpha]_D^{22} -46.1^\circ$ (c 1.15, H₂O); UV (H₂O) λ_{\max} 272 nm (ϵ 8320); ¹H NMR (270 MHz, D₂O) δ 1.96 (m, H-2'a), 2.56 (m, H-3'), 2.74 (m, H-2'b), 3.46-3.58 (2 dd, H-6'a,b), 3.68 (dd, H-5'a), 3.85 (dd, H-5'b), 4.25 (m, H-5), 6.09 (t, H-1), 7.79 (d, H-6). Anal. Calcd. for C₁₀H₁₄O₃N₆: C, 45.10; H, 5.30; N, 31.57. Found: C, 44.87; H, 5.13; N, 31.37. β $[\alpha]_D^{22} 55.0^\circ$ (c 0.99, H₂O); UV (H₂O) λ_{\max} 272 nm (ϵ 8209); ¹H NMR (270 MHz, D₂O) δ 2.22-2.58 (m, H-2' and H-3'), 3.48-3.61 (2 dd, H-6'), 3.79 (dd, H-5'a), 3.94 (dd, H-5'b), 4.0

(m, H-4'), 6.04 (d, H-5), 6.11 (dd, H-1'), 7.93 (d, H-6). Anal. Calcd. for $C_{10}H_{14}O_3N_6$: C, 45.10; H, 5.30. Found: C,; H,.

EXAMPLE 16

9-[2',3'-Dideoxy-3'-C-(azidomethyl)- α and β -D-erythro-pentofuranosyl]-adenine.

6-chloropurine (360 mg, 2.33 mmol) was silylated according to the general procedure and the synthesis was proceeded as above to give the title compounds α (38 mg, 17 %) and β (39 mg, 17 %). An analytical sample of each of the anomers was obtained by HPLC purification (water-methanol, 70:30, v/v). α : $[\alpha]^{22}_D +58.3^\circ$ (c 1.0, H_2O); UV (H_2O) λ_{max} 260 nm (ϵ 9353); 1H NMR 270 MHz, D_2O) δ 2.43 (m, H-2'a), 2.67 (m, H-3'), 2.84 (m, H-2'b), 3.61 (d, H-6'), 3.73 (dd, H-5'a), 3.88 (dd, H-5'b), 4.28 (m, H-4'), 6.28 (t, H-1'), 8.11 (s, H-2), 8.28 (s, H-8). Anal. Calcd for $C_{11}H_{14}O_2N_8$: C, 45.51; H, 4.86; N, 38.61. Found: C, 45.31; H, 4.80; N, 38.30. β : $[\alpha]^{22}_D -27.6^\circ$ (c 1.05, H_2O); UV (H_2O) λ_{max} 260 nm (ϵ 14102); 1H NMR 270 MHz, D_2O) δ 2.52 (m, H-2'a), 2.75 (m, H-2'b, H-3'), 3.61 (dd, H-6'a), 3.64 (dd, $J_{3,6'b} = 6.2$ Hz, H-6'b), 3.71 (dd, H-5'a), 3.88 (dd, H-5'b), 4.12 (m, H-4'), 6.36 (dd, and 3.0 Hz, H-1'), 8.19 (s, H-2), 8.33 (s, H-8). Anal. Calcd for $C_{11}H_{14}O_2N_8$: C, 45.51; H, 4.86; N, 38.61. Found: C, 45.28; H, 4.97; N, 38.36.

Example 17

9-[3S,4S)-3,4-di(hydroxymethyl)cyclopentyl]-guanosine
To a white suspension of PPh_3 (528 mg, 2.0 mmol) and 2-NH₂-6-Cl-purin (342 mg, 2.0 mmol in dry THF (14 ml) at room temperature under nitrogen, was added DEAD (Diethylazodicarboxylate) (0.33 ml, 2.3 mmol) and the yellowish suspension was stirred for an additional 4 h. 3,4-dibenzoyloxymethyl-cyclopentanol (200 mg, 0.57 mmol) in dry THF (5 ml) was added, and the mixture was stirred for an additional 30 min. The solvent was evaporated and the crude residue was purified by silica gel column chromatography (toluene-ethyl acetate, 1:1). The crude product was dissolved in MeOH (2 ml), aqueous NaOH(1M, 2ml) was added dropwise, and the mixture was stirred at 80°C for 4 h. After cooling, the reaction mixture was

neutralized with aqueous HCl (2M), the aqueous phase was extracted several times with THF-Ethylacetate (1:1) and the solvents were evaporated. The crude product was purified by silica gel column chromatography (chloroform-methanol, 6:1). Recrystallisation from water afforded the title compound in a yield of 57 g (36%).

Example 18

1-(2',3'-Dideoxy-2'-C-hydroxymethyl- β -D-erythro-pentofuranosyl)-thymine

A mixture of thymine (253 mg, 2.01 mmol), chlorotrimethylsilane (0.300 ml) and some crystals of $(\text{NH}_4)_2\text{SO}_4$ in hexamethyldisilazane (4 ml) was refluxed under nitrogen for 6 h. The clear solution was concentrated and residual volatiles were co-evaporated with added toluene (5 ml). The residue was dissolved in a mixture of dichloromethane-acetonitrile (9:1, 10 ml) and a solution of 2-C-acetoxymethyl-1-O-acetyl-5-O-(tert-butylidiphenyl)silyl-D-erythro-pentofuranose (630 mg, 1.34 mmol) in the same solvent mixture as above (5 ml) was added. The solution was cooled on an ice bath and tert-butyldimethylsilyl triflate (0.370 ml, 1.16 mmol) was added dropwise. The mixture was stirred for 30 min on an ice bath followed by 15 h at room temperature. Pyridine (2 ml) was added and the mixture was filtered through a pad of silica gel. The filtrate was concentrated and the residue purified by column chromatography (toluene-acetone 1:1) to yield 1-(2'-C-acetoxymethyl-5'-O-tert-butylidiphenylsilyl-2',3'-dideoxy- β -D-erythro-pentofuranosyl)-thymine. 100 mg, 0.186 mmol of this material was dissolved in 1 M tetrabutylammonium fluoride \times 3 H_2O in THF (9 ml) and stirred for 20 min at room temperature. The solution was concentrated and the residue purified by column chromatography (toluene-acetone 1:1). The product was dissolved in methanol (4 ml) and methanol saturated with ammonia (2 ml) was added. The solution was stirred over night, concentrated and the residue purified by column chromatography (chloroform-methanol 9:1) yielding the title compound (38 mg): $[\alpha]_D +9.1^\circ$ (c 0.70, H_2O): ^{13}C NMR (D_2O , 40°C) 12.3 (CH_3 , thymine), 29.2 (C-3'), 46.7 (C-2'), 62.4, 63.8 (C-5', C-6'), 81.0 (C-4'), 88.8 (C-1'), 112.2 (C-5), 138.6 (C-6), 152.5 (C-4), 167.2; ^1H NMR (D_2O , 40°C) 1.90 (s, 3H, CH_3 , thymine), 2.09 (m, 2H, H-3', H-3''), 2.64 (m, 1H, H-2'), 3.76 (m,

4H, H-5', H-5'', H-6', H-6''), 4.31 (m, H-4'), 5.93 (d, J=5.13 Hz, 1H, H-1'), 7.68 (s, 1H, H-6).

Anal. Calcd. for $C_{11}H_{16}O_5N_2$: C, 51.56; H, 6.29; N, 10.93. Found: C, 51.28; H, 6.11; N, 10.71.

EXAMPLE 19

1-(2',3'-Dideoxy-2'-C-hydroxymethyl- β -D-erythro-pentofuranosyl)cytosine was synthesized analogous to Example 12 using cytosine instead of thymine yielding (41 mg): $[\alpha]_D + 31.2^\circ$ (c 1.20, H_2O): ^{13}C NMR (D_2O , $40^\circ C$) 29.2 (C-3'), 47.6 (C-2'), 62.5, 64.0 (C-5', C-6'), 81.2 (C-4'), 89.8 (C-1'), 96.8 (C-5), 142.6 (C-6). 158.3 (C-4), 166.9 (C-2); 1H NMR (D_2O , $40^\circ C$) 2.04 (m, 2H, H-3', H-3''), 2.55 (m, 1H, H-2'), 3.77 (m, 4H, H-5', H-5'', H-6', H-6''), 4.33 (m, 1H, H-4'), 5.91 (d, J=4.77 Hz, 1H, H-1'), 6.05 (d, J= 7.32 Hz, 1H, H-5), 7.85 (d, J= 7.32 Hz, 1H, H-6).

Anal. Calcd. for $C_{10}H_{15}O_4N_3 \times H_2O$: C, 46.33; H, 6.61; N, 16.21. Found: C, 46.41; H, 6.31; N, 16.16.

EXAMPLE 20

2',3'-Dideoxy-2'-C-hydroxymethyladenosine was synthesized analogous to Example 12 using adenine instead of thymine yielding (20 mg): $[\alpha]_D -10.3^\circ$ (c 0.20, H_2O): UV (H_2O) γ_{max} 260 nm; ^{13}C NMR (D_2O , $40^\circ C$) 29.4 (C-3'), 46.8 (C-2'), 62.2, (C-5', C-6'), 81.4 (C-4'), 88.3 (C-1'), 141.2-169.4 (5ArC); 1H NMR (D_2O , $40^\circ C$) 2.21 (m, 2H, H-3', H-3''), 3.06 (m, 1H, H-2'), 3.76 (m, 4H, H-5', H-5'', H-6', H-6''), 4.45 (m, 1H, H-4'), 6.07 (d, J= 5.32 Hz, 1H, H-1'), 8.15, 8.30 (s, s, 2H, H-2, H-8).

Anal. Calcd. for $C_{11}H_{15}O_3N_5$: C, 49.81; H, 5.70; N, 26.40. Found: C, 50.01; H, 5.54; N, 26.35.

EXAMPLE 21

1-(2'-C-Azidomethyl-2',3'-dideoxy- β -D-erythro-pentofuranosyl)-thymine.

A solution 1-(2'-C-acetoxymethyl-5'-O-tert-butylidiphenyl-2',4'-dideoxy- β -D-erythr -pentofuransyl)thymine (440 mg, 0.820 mmol) in methanol saturated with ammonia (15 ml) was stirred ver night. The mixture was concentrated and the residue purified by c lumn chromatography (toluene-acetone 1:1).

The residue (170 mg, 344 μ mol) was dissolved in pyridine (5 ml) and methanesulfonyl chloride (0.030 ml, 379 μ mol) was added. After 1 h at room temperature, the solution was concentrated and the residue co-evaporated with added toluene. The residue was purified by column chromatography (toluene-acetone 2:1) yielding 1-(5'-O-tert-butylidiphenylsilyl-2'-C-methanesulfonylmethyl-2',3'-dideoxy- β -D-erythro-pentofuranosyl)thymine which was dissolved in DMF (2 ml). Sodium azide (72 mg, 1.11 mmol) was added and the resulting suspension was stirred at 60°C for 3 h. The mixture was concentrated and purified by column chromatography (toluene-acetone 2:1) (151 mg) (IR(CHCl₃) 2100 cm⁻¹), which was dissolved in 1 M tetrabutylammonium fluoride x 3 H₂O in THF (10 ml) at room temperature. After 10 min, the mixture was concentrated and the residue purified by column chromatography (toluene-acetone 1:1) yielding the title compound (72 mg). [α] D -31.3° (c 0.76, CHCl₃): IR (CHCl₃) 2100 cm⁻¹ (azide): ¹³C NMR (CDCl₃) 12.5 (CH₃, thymine), 29.6 (C-3'), 44.5 (C-3), 52.0 (C-6'), 63.8 (C-5'), 79.8 (C-4'), 89.0 (C-1'), 111.0 (C-5). 136.6 (C-6), 150.9 (C-4), 164.4 (C-2); ¹H NMR (CDCl₃) 1.89 (s, 3H, CH₃, thymine), 1.96 (m, 1H, H-3'), 2.28 (m, 1H, H-3''), 2.61 (m, 1H, H-2'), 3.53, 3.82 (m, m, 4H, H-5', H-5'', H-6', H-6''), 4.29 (m, 1H, H-4') 5.81 (d, J=5.50 Hz, 1H, H1', 7.56 (s, 1H, H-6), 9.90 (s, 1H, H-3).

Anal. Calcd. for C₁₁H₁₅O₄N₃: C, 46.97; H, 5.38; N, 24.90. Found: C, 46.83; H, 5.21; N, 24.71.

EXAMPLE 22

2'-C-Azidomethyl-2',3'-dideoxycytidine

A solution of 2'-C-acetoxymethyl-5'-O-tert-butylidiphenyl-2',3'-dideoxy-cytidine (260 mg, 0.489 mmol) in methanol saturated with ammonia (10 ml) was stirred over night at room temperature. The mixture was concentrated and the residue purified by column chromatography (chloroform-methanol 9:1) to give 395 mg of the de-o-acetylated cytidine analogue. To a stirred solution of this material (100 mg, 0.208 mmol) in pyridine (3 ml) was added methanesulfonyl chloride (0.020 ml, 0.250 mmol). After 1 h the solution was concentrated and the residue was coevaporated with added toluene. The residue was purified by column chromatography (chloroform-methanol 9:1) (110

mg) ^{13}C NMR (CDCl_3) 37.3 (CH_3), 69.7 (C-6'); ^1H NMR (CDCl_3) 3.08 (s, 3H, CH_3), 4.50 (d, $J=4.21$ Hz, 2H, H-6', H-6''). 100 mg, 0.179 mmol of this compound was dissolved in DMF (2 ml) and sodium azide (41 mg, 0.628 mmol) was added. The resulting suspension was stirred at 60°C for 3.5 h. The mixture was concentrated and the residue purified by column chromatography (toluene-acetone 2:1) (84 mg), ($\text{IR}(\text{CHCl}_3)$ 2100 cm^{-1}) this was dissolved in 1M tetrabutylammonium fluoride x 3 H_2O in THF (4 ml) at room temperature. After 15 min, the mixture was concentrated and the residue purified by column chromatography (chloroform-methanol 5:1) and then HPLC (reversed phase, methanol-water 85:15) yielding the title compound (36 mg): $[\alpha]_D^{25} +54.4^\circ$ (c 0.95, H_2O): $\text{IR}(\text{CHCl}_3)$ 2100 cm^{-1} , (azide): ^{13}C NMR (D_2O , 40°C) 29.9 (C-3'), 44.9 (C-2'), 52.6 (C-6'), 64.0 (C-5'), 80.8 (C-4'), 90.0 (C-1'), 97.1 (C-5), 142.6 (C-6), 158.3 (C-4), 166.9 (C-2); ^1H NMR (D_2O , 40°C) 2.03 (m, 2H, H-3', H-3''), 2.61 (m, 1H, H-2'), 3.56 (m, 2H, H-6', H-6''), 3.75 (m, 2H, H-5', H-5''), 4.33 (m, 1H, H-4'), 5.92 (d, $J=5.50$ Hz, 1H, H-1'), 6.05 (d, $J=7.32$ Hz, 1H, H-5), 7.82 (d, $J=7.32$ Hz, 1H, H-6).

Anal. Calcd. for $\text{C}_{10}\text{H}_{14}\text{O}_3\text{N}_6$: 45.11; H, 5.30; N, 31.56. Found: C, 45.02; H, 5.41; N, 31.28.

EXAMPLE 23

1-[5'-O-Benzoyl-3'-C-[(benzoyloxy)methyl]-2',3'-dideoxy-4'-thio- α -and- β -D-erythro-penta-furanosyl]thymine(18).

A suspension of thymine (150 mg, 1.19 mmol) and a small crystall of ammonium sulfate in a mixture of hexamethyldisilazane (2 ml) and trimethylchlorosilane (0.2 ml) was refluxed until a clean solution was obtained. Volatile matters were evaporated off and the residue was repeatedly co-evaporated with toluene. The resulting syrup was dissolved in dichloromethane (2 ml) under nitrogen. To this solution compound 16 (153 mg, 0.32 mmol) was added followed by the addition of tert.-butyldimethylsilyl triflate (0.075 mL, 0.33 mmol), mercuric acetate (0.102 g, 0.32 mmol). The solution was stirred for 24 h at room temperature. The reaction was quenched by the addition of saturated aqueous sodium hydrogen carbonate, dried, concentrated and purified by column chromatography (chloroform-ethyl acetate 1:1) to give (0.127 g, 87 %). NMR indicated that

coupling of thymine had occurred but the spectra were too complex to analyse without separating the anomers. This material was de-O-benzoylated using sodium in methanol at room temperature to give 1(3'-C-hydroxymethyl)-2',3'-dideoxy 4'-thio- α -and- β -D-erythro-pentofuranosyl)thymine.

EXAMPLE 24

1-[5'-O-Benzoyl-3'-C-[(benzoyloxy)methyl]-2',3'-dideoxy-4'-thio- α -and- β -D-erythro-pentofuranosyl]cytosine. Cytosine (100 mg, 0.901 mmol) was silylated following the same procedure as for the preparation of 18 and dissolved in acetonitrile (3 ml) under nitrogen. Compound 17 (119 mg, 0.287 mmol) was added followed by the addition of tert.-butyldimethylsilyl triflate (0.13 ml, 0.574 mmol) and the solution was stirred for 1 h at 0°C. The reaction was quenched by the addition of saturated aqueous sodium hydrogen carbonate, stirred for 30 min, diluted with dichloromethane, washed with saturated aqueous sodium hydrogen carbonate, dried, concentrated and purified by column chromatography (ethyl acetate-methanol 4:1) to give an anomeric mixture of the protected nucleoside 19 (49 mg, 37 %). NMR indicated that coupling of cytosine had occurred but the spectra were too complex to analyse without separating the anomers. This material was de-O-benzoylated using sodium in methanol at room temperature to give 1(3'-C-hydroxymethyl)-2',3'-dideoxy 4'-thio- α -and- β -D-erythro-pentofuranosyl)cytosine.

Experimental

The starting materials for the compounds in Examples 1-4 were prepared by the following sequence of reactions a - d:

a) (2S,3R)-1-O-p-Bromobenzyl-3-C-(2'-propenyl)-1,2,4-butanetriol (compound 2, Scheme 1). To a cold solution of allylmagnesium bromide -50°C (20 ml, 1M) in 100 ml of dry diethyl ether under nitrogen atmosphere, a solution of (2S,3R)-3-[[4-bromobenzyl]oxy]methyl]oxirane-2-methanol-1 (1.36 g, 5 mmol) in 140 ml of dry diethyl ether was added dropwise over 30 minutes. The mixture was vigorously stirred for

30 minutes at -50°C and then quenched with saturated aqueous ammonium chloride. The organic phase was collected and the aqueous phase was extracted with diethyl ether. The organic phases were combined and washed with hydrogen chloride (1M), sodium hydrogen carbonate (sat.), dried, filtered, concentrated and separated by column chromatography (toluene: ethyl acetate, 1:5), to give 2 (1 g, 64 %) [and 3 (0.4 g, 25 %)], $[\alpha]_{\text{D}}^{22}$: +1.56 (c 1.03, CHCl_3); $^1\text{H-NMR}$ (100 MHz, CDCl_3): 1.8 (m 1H, H-3); 2.13 (t, $J_{1',2'} = J_{1',3} = 6.8$ Hz, 2H, H-1'); 3.3 and 3.0 (broad, 2H, OH-2); 3.59 (m, 4H, H-1, H-4); 4.0 (m, 1H, H-2); 4.48 (s, 2H, CH_2Ph); 4.94 and 5.09 (m, 2H, H-3'a, H-3'b); 5.78 (m, 1H, H-2'); 7.14-7.5 (m, 4H, arom); $^{13}\text{C-NMR}$ (25.05 MHz, CDCl_3): 30.6 (C-1'); 42.3 (C-3); 53.3 (C-4); 71.9, 72.3, 72.5 (CH_2Ph , C-1, C-2'); 116.4 (C-3'); 121.5, 129.1, 131.3 (aromatic C); 136.4 (C-2 and aromatic C);

b) (2S,3R)-4-O-Benzoyl-1-O-p-bromobenzyl-3-C-(2'-propenyl)-1,2,4-butan-triol (compound 4, scheme 1). Benzoyl chloride (3.21 ml, 27.6 mmol) was added dropwise to a solution of compound 2 (8.54 g, 27 mmol) in dry pyridine (50 ml) at 0°C . The reaction mixture was stirred at 0°C for 15 minutes. Water (5 ml) was added and the solvent was evaporated. The residue was dissolved in dichloromethane and washed with hydrochloric acid (1 M), aqueous sodium hydrogen carbonate (sat.), dried, concentrated and purified by flash chromatography (toluene: ethyl acetate, 2:1) to give compound 4 (9.77 g, 86 %). $[\alpha]_{\text{D}}^{22}$: +8.5 (c 0.71, CHCl_3); $^1\text{H-NMR}$ (100 MHz, CDCl_3): 1.95-2.43 (m, 3H, H-3, H-1'); 2.59 (d, $J_{\text{H(OH)},2} = 3.9$ Hz, 1H, OH-2); 3.54 (m, sec. order, 2H, H-1a, H-1b); 3.95 (m, 1H, H-2); 4.34 (d, $J_{4,3} = 5.1$ Hz, 2H, H-4); 4.48 (s, 2H, CH_2Ph); 5.14 and 5.0 (m, 2H, H-3'a, H-3'b); 5.78 (m, 1H, H-2'); 8.1-7.14 (m, 9H, arom.); $^{13}\text{C-NMR}$ (25.05 MHz, CDCl_3): 31.3 (C-1'); 40.4 (C-3); 70.1 (C-2); 64.0 (C-4); 72.3 (CH_2Ph); 72.5 (C-1); 116.3 (C-3'); 121.4-134.7 (arom.); 136.4 (C-2'); 166.1 (COPh).

c) Methyl 3-C-[(benzoyloxy) methyl]-5-O-p-bromobenzyl-2,3-dideoxy-D-erythro-pentofuranoside (compound 5, scheme 1). To an ice cold mixture of compound 4 (7.5 g, 17.9 mmol) and N-methylmorpholine-N-oxide (4.8 g, 35.5 mmol) in

tetrahydrofuran:water (3:1, 70 ml), OsO_4 in t-butanol (18 ml, 0.02 M, stab. with 1 % TBHP, 0.36 mmol) was added. After a few minutes, the ice bath was removed and the reaction mixture was stirred overnight at room temperature under nitrogen. NaHSO_3 (2 g) was added and the mixture was stirred for 15 minutes. The solvent was evaporated off and the residue diluted with ethyl acetate, washed with HCl (1 M), NaHCO_3 (sat.), dried, filtered and concentrated. The crude product was dissolved in tetrahydrofuran:water (3:1, 200 ml) and treated with NaIO_4 (7.65 g, 35.8 mmol). The cis diol was completely cleaved after 30 minutes at room temperature. The tetrahydrofuran was evaporated off and the aqueous residue was saturated with NaCl, and extracted with diethyl ether. The organic phase was dried and concentrated. The residue was treated with methanolic HCl (0.05 %, 50 ml) for ten minutes, neutralized with Dowex 2x8 (HCO_3^-), filtered, evaporated and the residue was purified by flash chromatography (toluene-ethyl acetate, 3:1) to give an anomeric mixture of compound 5 (6.63 g, 85 %) as a colourless syrup.

^1H -NMR (100 MHz, CDCl_3): 1.7-2.9 (three m, 3H, H-3, H-2a, H-2b); 3.31, 3.35 (2s, 3H, OCH_3); 3.6 (m, 2H, H-5); 4.1 (m, 1H, H-4); 4.4 (m, 2H, H-6); 4.6 (m, 2H, CH_2Ph); 5.1 (m, 1H, H-1); 7.1-8.0 (m, 9H, aromatic); ^{13}C -NMR (25.05 MHz, CDCl_3): 35.6, 36.4 (C-2); 38.7, 39.3 (C-3); 54.3, 54.5 (OCH_3); 65.7, 66.6, (C-6); 71.5, 72.35, 72.37, 73.8 (C-5) (CH_2Ph); 79.9, 80.1 (C-4); 104.8 (C-1); 121.0-136.4 (aromatic); 165.8 (COPh).

d) Methyl 5-O-benzoyl-3-C-[(benzoyloxy)methyl]-2,3,-dideoxy-D-erythro-pentafuranoside (compound 6, scheme 1). A solution of compound 5 (1 g, 2.3 mmol) in dry diethyl ether (3 ml) was dissolved in liquid ammonia (50 ml) in a dewar bottle. Sodium (300 mg, 13 mmol) was added in portions over 5 minutes. The solution was stirred for 30 minutes and then quenched with solid NH_4Cl . The ammonia was evaporated under a stream of nitrogen and the solid residue was diluted with ethyl acetate. The solid was filtered off and washed several times with ethyl acetate. The filtrate was concentrated and then co-evaporated with dry toluene. The crude residue was dissolved in dry pyridine (30 ml). Benzoylchloride (0.8 ml, 6.9 mmol) was added and the solution was stirred for 40 minutes at room temperature

after which water (5 ml) was added and the mixture was concentrated to dryness. The residue was dissolved in CH_2Cl_2 and washed with aqueous HCl (1 M), aqueous NaHCO_3 (sat.), dried, filtered and evaporated to dryness. Flash chromatography (toluene ethyl acetate, 3:1) yielded compound 6 (580 mg, 68 %), as an anomeric mixture. A small sample of compound 6 was separated by silica gel. $^1\text{H-NMR}$ and m.p. of the β -anomer were in agreement with those previously reported.

The starting materials for the compounds in Examples 11-16 were prepared by the following sequence of reactions a-e:

a) Methyl 5-O-(p-bromobenzyl)-3-C-(hydroxymethyl)-2,3-dideoxy-D-erythro-pentofuranoside. Methyl 3-C-[(benzoyloxy)-5-O-(α -bromobenzyl)-2,3-dideoxy-D-erythro-pentofuranoside (1.61 mg, 3.70 mmol) was treated with methanolic ammonia (30 ml, saturated) for 24 h. The solvent was evaporated, and the residue was purified by flash column chromatography (toluene-ethyl acetate, 1:2) to give the title compound (1.14 g, 93 %). Anal. Calcd for $\text{C}_{14}\text{H}_{19}\text{O}_4\text{Br}$: 50.77; H, 5.78. Found: C, 50.67; H, 5.73.

b) Methyl 5-O-(p-bromobenzyl)-3-C-(fluoromethyl)-2,4-dideoxy-D-erythro-pentofuranoside. To a cold solution (-15°C) of the previous compound (637 mg, 1.92 mmol) in dichloromethane (15 ml) and pyridine (0.31 ml, 3.85 mmol) under nitrogen, a solution of trifluoromethanesulfonic anhydride (0.38 ml, 2.26 mmol) in dichloromethane (5 ml) was added dropwise. After stirring for 10 min at -15°C , the mixture was diluted with dichloromethane (100 ml), washed with 1 M hydrogen chloride, saturated aqueous sodium hydrogen carbonate, dried, and concentrated at a bath temperature not exceeding 20°C . The residue was treated with a solution of anhydrous tetrabutylammonium fluoride in tetrahydrofuran (6 ml, 1M) for 15 min. The mixture was concentrated and the residue was subjected to flash column chromatography (toluene-ethyl acetate, 9:1) to give the title compound (466 mg, 73 %). Anal. Calcd for $\text{C}_{14}\text{H}_{18}\text{O}_3\text{BrF}$: 50.46; H, 5.45. Found: C, 50.28; H, 5.35.

c) Methyl 5-p-benzoyl-3-C-(fluoromethyl)-2,3-dideoxy-D-erythro-pentofuranoside. A mixture of the previous compound (572 mg, 1.72 mmol) in ethanol (40 ml) containing sodium hydrogen carbonate (excess) and 10 % Pd on charcoal (50 mg) was treated with hydrogen for 5 h at ambient pressure. The solids were filtered off and the filtrate was concentrated. The crude residue was dissolved in a mixture of dichloromethane (3 ml) and pyridine (0.3 ml, 3.7 mmol), followed by the addition of benzoyl chloride (0.24 ml, 2.07 mmol). The reaction mixture was stirred for 15 min. Water (2 ml) was added, and the mixture was stirred for 10 min, diluted with dichloromethane, washed with 1 M hydrogen chloride, saturated aqueous hydrogen carbonate, dried, and concentrated. The residue was purified by flash column chromatography (toluene-ethyl acetate, 4:1) to give the title compound (372 mg, 81 %). Anal. Calcd. for $C_{14}H_{17}O_4F$: C, 62.68; H, 6.39. Found: C, 62.55; H, 6.33.

d) Methyl 3-C-(azidomethyl)-5-O-(p-bromobenzyl)-2,3-dideoxy-D-erythro-pentofuranoside.

To a mixture of methyl 5-O-(p-bromobenzyl-3-C-(hydroxymethyl)-2',3'-dideoxy-D-erythro-pentofuranoside (1.95 g, 5.89 mmol), triphenylphosphine (1.6 g, 6.1 mmol), and lithium azide (1.5 g, 30.6 mmol) in dry N,N-dimethylformamide (25 ml) was added carbon tetrabromide (1.95 g, 5.89 mmol) at room temperature. The mixture was vigorously stirred for 24 h. Methanol (3 ml) was added, and the solvent was evaporated. The mixture was diluted with dichloromethane, washed with water, dried, and concentrated. The residue was purified by flash column chromatography (toluene-ethyl acetate, 4:1) to give the title compound (1.99 g, 95 %) γ_{\max} 2100 cm^{-1} . Anal. Calcd. for $C_{14}H_{18}O_3BrN_3$: C, 47.20; H, 5.09; N, 11.80. Found; C, 47.15; H, 4.98; N, 11.9.

e) Methyl 3-C-(azidomethyl)-5-O-(benzoyl)-2,3-dideoxy-D-erythro-pentofuranoside. To a stirred solution of dry pyridine (4.7 ml, 58.3 mmol) and dichloromethane (20 ml) was added chromium tri oxide (2.8 g, 28.0 mmol). The mixture was stirred for 15 min at room temperature. A solution of the previous compound (1.68 g, 4.72 mmol) in dichloromethane (20 ml) was

added, followed by acetic anhydride (3.2 ml, 32.0 mmol), and the mixture was stirred for 10 min at room temperature. The mixture was passed through a short column of silica gel with ethyl acetate as eluent, to give a crude product, which was treated with methanolic ammonia (30 ml, saturated) for 24 h. The solvent was evaporated, and the residue was purified by flash column chromatography (toluene-ethyl acetate, 1:1) and then dissolved in a mixture of dichloromethane (15 ml) and pyridine (1 ml, 12.4 mmol), after which benzoyl chloride (0.55 ml, 4.73 mmol) was added. The reaction mixture was stirred for 15 min. Water (2 ml) was added, and the mixture was stirred for 10 min, diluted with dichloromethane, washed with 1 M hydrogen chloride, saturated aqueous hydrogen carbonate, dried, and concentrated. The residue was purified by flash column chromatography (toluene-ethyl acetate, 9:1) to give the title compound (1.0 g 57 %). Anal. Calcd for $C_{14}H_{17}O_4N_3$: C, 57.72; H, 5.88; N, 14.43. Found: C, 57.86; H, 5.74; N, 14.43.

The starting material for the compounds in Example 17 were prepared by the following sequence of reactions a-b:

a) (3S,4S)-3,4-di(benzoyloxymethyl)cyclopentanone (compound 8, Scheme 2). A mixture of (-)-(3S,4S)-3,4-di(methoxycarbonyl)-cyclopentanone (compound 7, Scheme 2) (0.93 g, 4.6 mmol), ethylene glycol (6.5 ml, 0.12 mol) and p-toluenesulfonic acid monohydrate (25 mg) in toluene (50 ml) was refluxed for 6 h with a Dean-Stark trap. Sodium hydrogen carbonate (20 mg) was added and after stirring for 5 min the mixture was washed with saturated aqueous sodium hydrogen carbonate, dried ($MgSO_4$) and concentrated to a crude ketal diester. According to 1H NMR, the product was free from unreacted ketone. The crude ketal diester in dry diethyl ether (15 ml) was added dropwise for 1 h to an ice-cold mixture of lithium aluminium hydride (0.35 g, 9.2 mmol) in dry diethyl ether (35 ml). The mixture was stirred at room temperature for 3 h before the excess of lithium aluminium hydride was decomposed by successive addition of water (0.5 ml), 3 M aqueous NaOH (0.5 ml) and water (1.5 ml). After stirring for 1 h $MgSO_4$ (20 g) was added and the stirring was prolonged for 5 min. The precipitate and $MgSO_4$ were removed by filtration and washed several times.

with ethyl acetate. The filtrate was concentrated to give a crude oil of the diol. To a stirred solution of the diol in pyridine (13.5 ml) was added benzoyl chloride (2.3 ml, 20.1 mmol) dropwise. The mixture was stirred for 3 h in room temperature. Water (5 ml) was added and after stirring for 10 min, the mixture was diluted with saturated aqueous sodium hydrogen carbonate and dichloromethane. The organic layer was separated and washed with saturated sodium hydrogen carbonate, dried (MgSO_4) and concentrated. Column chromatography (toluene-EtOAc, 3:1) on a short column of silica gel gave a syrupy residue including the dibenzoylated ketal and traces of the dibenzoylated ketone. The syrup was dissolved in methanol (92 ml) and 2 M aqueous HCl (31 ml), stirred at room temperature for 2 h and then at 50°C for additional 2 h. The solution was neutralized with sodium hydrogen carbonate (5.2 g), diluted with water, extracted with dichloromethane. The organic layer was dried (MgSO_4), concentrated and crystallized from diethyl ether/hexane to give the title compound as needles (0.90 g, 55%): m.p. 85-86°C; $[\alpha]_D -59.1^\circ$ (c 1.04, chloroform); ^1H NMR (100 MHz, CDCl_3) δ 2.12-2.73 (m, 6H, 2 CH, 2 CH_2), 4.50 (d, 4H, 2 $\text{CH}_2\text{-OBz}$), 7.36-7.64 and 7.94-8.07 (m, 10H, aromatic H); ^{13}C NMR (25.05 MHz, CDCl_3) δ 38.3 (2 CH_2), 41.6 (2 CH) 65.9 (2 $\text{CH}_2\text{-OBz}$), 128.2, 128.2 and 133.0 (aromatic C), 165.9 and 214.9 (C=O). Anal. Calcd for $\text{C}_{21}\text{H}_{20}\text{O}_5$ (352.4): C, 71.58; H, 5.72. Found: C, 71.34; H, 5.73.

b) (3S,4S)-3,4-di(benzoyloxymethyl)cyclopentanol (compound 9, Scheme 2). To the compound 8 obtained under a) (193 mg, 0.55 mmol) in methanol (10 ml) was added sodium borohydride (41 mg, 1.10 mmol) in successive portions. The mixture was stirred at room temperature for 30 min, and then diluted with water and diethyl ether. The organic layer was washed with saturated aqueous sodium chloride, dried (MgSO_4) and concentrated to a syrup which was purified by column chromatography on silica gel (toluene/EtOAc, 1:1) to yield title compound (189 mg, 97%; $[\alpha]_D -16.4^\circ$ (c 1.09, chlor form); ^1H NMR (100 MHz, CDCl_3) δ 1.6-2.7 (m, 7H, 2 CH, 2 CH_2 , OH), 4.41 (t, 4H, 2 $\text{CH}_2\text{-OBz}$), 7.34-7.56 and 7.97-8.09 (m, 10H, aromatic H); ^{13}C NMR (25.05 MHz, CDCl_3) δ 38.3, 39.3, 39.8, 40.0 (2 CH_2 2 CH), 67.4, 68.2 (2 $\text{CH}_2\text{-OBz}$), 72.5

(CHOH), 128.1, 129.3, 129.8, 132.8 (aromatic C), 166.3 (C=O).
 Anal. Calcd for $C_{21}H_{22}O_5$ (354.4): C, 71.17; H, 6.26. Found: C, 71.05; H, 6.18.

The starting materials for the compounds in Examples 18 - 22 were prepared by the following sequence of reactions a-c:

a) (S)-4-tert-Butyldiphenylsilyloxy)methyl-(R,S)-2-hydroxymethyl- γ -butyrolactone (11). Ethanol (28 μ l, 0.48 mmol) was added to sodium (280 mg, 12.17 mmol) in dry diethyl ether (5 ml), and the mixture was stirred at room temperature for 2 h. A solution of (S)-4-(tert-butyldiphenylsilyloxy)methyl- γ -butyrolactone (3.50 g, 9.87 mmol) and ethyl formate (960 mg, 13.23 mmol) in diethyl ether (6 ml) was added and the stirring was continued for 16 h at room temperature. Diethyl ether (20 ml) and 1 M NaH_2PO_4 (10 ml) were added and the phases were separated. The organic phase was washed with water, dried and concentrated. The residue was dissolved in ethanol (10 ml), and a solution of $NaBH_4$ (500 mg, 13.22 mmol) in ethanol (10 ml) was added. After 5 min, the reaction was terminated by the addition of a few drops of 80 % acetic acid. The mixture was partitioned between ethyl acetate and water. The organic phase was dried, concentrated and the residue purified by column chromatography (toluene-acetone 9:1) yielding 11 (3.40 g, 90 %).

Anal. Calcd for $C_{22}H_{28}O_4Si$: C, 68.71; H, 7.34. Found: C, 68.58; H, 7.36.

b) (S)-2-Acetoxymethyl-(S)-4-(tert-butyldiphenylsilyloxy)methyl- γ -butyrolactone(12). A solution of 11 (2.00 g, 5.20 mmol) in pyridine (20 ml) and acetic anhydride (10 ml) was stirred at 60°C for 30 min. The solution was concentrated and the residue purified by column chromatography (toluene-acetone 10:1) to give 12 (1.41 g, 64 %): $[\alpha]_D +22.4^\circ$ (c 1.00, $CHCl_3$): ^{13}C NMR ($CDCl_3$) δ 29.3 (C, tert), 20.8 (CH_3 , acetate), 26.9 (3 x CH_3), 27.3 (C-3), 39.8 (C-2), 63.1, 65.7 (CH_2OAc , C-5), 78.1 (C-4), 127.9, 128.3-135.7 (ArC), 170.7 (ac tate), 176.4 (carbonyl); 1H NMR ($CDCl_3$) δ 1.05 (s, 9H, 3 x CH_3), 2.07 (s, 3H, CH_3 , acetate), 2.39 (m, 2H, H-3, H-3'), 3.13 (m, 1H, H-2), 3.79, 4.35 (m, m, 4H, H-5, H-5', H-6, H-6'), 4.58 (m, 1H, H-4), 7.17-7.72

(m, 10H, ArH).

Anal. Calcd. for $C_{24}H_{30}O_5Si$: C, 67.57; H, 7.09. Found: C, 67.48; H, 7.15.

c) 2-C-Acetoxymethyl-1-O-acetyl-5-O-(tert-butyldiphenyl)-silyl-D-erythro-pentofuranose (13). To a solution of lactone 12 (500 mg, 1.17 mmol) in toluene (30 ml) at $-78^{\circ}C$ was added diisobutylaluminium hydride (20 % in hexane, 3.00 ml, 2.95 mmol). The solution was stirred for 1.5 h, allowed to warm to room temperature, and methanol (0.5 ml) was added. To the solution was added ethyl acetate (30 ml) and aqueous sat. $NaHCO_3$ (4 ml). After stirring for 2 h, dry $MgSO_4$ (2.0 g) was added and after additional stirring for 3 h, the mixture was filtered. The filtrate was concentrated, the residue dissolved in pyridine (6 ml) and acetic anhydride (3 ml) and heated to $40^{\circ}C$ for 30 min, concentrated and the residue purified by column chromatography (toluene-acetone 10:1) to yield the title compound (500 mg, 91 %) as an anomeric mixture. ^{13}C NMR ($CDCl_3$, selected signals) δ 19.4 (C, tert.), 20.9, 21.3, 21.4 (CH_3 , acetates), 26.9 (3 x CH_3), 28.4 (C-3), 42.3, 44.8 (C-2), 62.8, 63.7, 65.8, 66.8 (C-5 and C-6), 80.0, 81.4 (C-4), 97.6, 100.2 (C-1), 127.8-135.7 (ArC), 170.2, 170.9 (acetates).

Anal. Calcd. for $C_{26}H_{34}O_6Si$: C, 66.35; H, 7.29. Found: C, 66.51; H, 7.28.

The starting materials for the compounds in Examples 23 - 24 were prepared by the following sequence of reactions a-c:

a) 5-O-Benzoyl-3-C-[(benzoyloxy)methyl]-2,3-dideoxy-L-threo-pentose dibenzyl dithioacetal (15).

Compound 14 (0.191 g, 0.516 mmol) was treated at room temperature with benzyl mercaptane (0.24 ml, 2.07 mmol) in dichloromethane (3 ml) containing a catalytic amount of stannic chloride for 24 hours. The mixture was then diluted with dichloromethane and washed with saturated aqueous sodium hydrogen sulfate, dried, filtered, concentrated and purified by flash column chromatography (toluene-ethyl acetate 9:1) to give compound 15 (0.266 g, 88 %) as a colorless syrup: $[\alpha]_D^{22} -8.1^{\circ}$ (c 1.0, $CHCl_3$). ^{13}C NMR (25.05 MHz, $CDCl_3$) δ 34.0, 34.6, 34.9 (C-2,

CH₂Ph), 38.9 (C-3), 47.9 (C-1), 63.2 (C-4), 67.6 (C-5), 69.8 (C-6), 127.1-138.0 (aromatic), 166.7 (COPh).

b) Benzyl 5-O-benzoyl-3-C-[(benzoyloxy)methyl]-2,3-dideoxy-1,4-dithio- α -and- β -D-erythro-pentofuranoside (**16**). To a solution of compound **15** (0.347 g, 0.592 mmol) in toluene-acetonitrile (2:1, 9 ml) were added triphenylphosphine (0.93 g, 3.55 mmol) and triiodoimidazole (0.79 g, 1.78 mmol). The mixture was kept at 100°C over night. The mixture was diluted with toluene and washed with saturated aqueous sodium hydrogen sulfate, dried, filtered, concentrated and purified by column chromatography (toluene-ethyl acetate 50:1) to give **16** (0.219 g, 77 %) as a colourless syrup: $[\alpha]^{22}_D -4.2^\circ$ (c 1.0, CHCl₃); ¹H NMR (100 MHz, CDCl₃) δ 2.0-2.3 (m, 2H, H-2), 2.8 (m, 1H, H-3), 3.8 (m, 3H, CH₂Ph, H-4), 4.5 (m, 5H, H-1, H-5, H-6), 7.1-8.1 (m, 15H, aromatic).

c) Acetyl 5-O-benzoyl-3-C-[(benzoyloxy)methyl]-2,3-dideoxy-4-thio- α -and- β -D-erythro-pentofuranoside (**17**). Compound **16** (0.182 g, 0.381 mmol) and mercuric acetate (0.243 g, 0.761 mmol) in glacial acetic acid (5 ml) were stirred at room temperature for 30 min. The solvent was evaporated and co-evaporated with dry toluene. The residue was diluted with dichloromethane, filtered through celite and concentrated. Flash chromatography (toluene-ethyl acetate 9:1) gave compound **17** (0.156 g, 99 %) as a colourless syrup: ¹H NMR (100 MHz, CDCl₃) δ 2.03, 2.07 (2s, 3H, COOCH₃), 2.3 (2H, H-2), 3.0 (m, 1H, H-3), 3.8 (m, 1H, H-4), 4.4 (m, 4H, H-5, H-6), 6.2 (m, 1H, H-1), 7.0-7.9 (m, 10H, aromatic).

Biological tests

Test I. Effect of compounds of the formula I on HIV in H9 cells

HIV infection of H9 cells

H9 cells, 10⁵ cells per well on a 24 well plate, suspended in 2 ml RPMI-medium containing 10 % fetal calf serum, 100 mg/ml penicillin, 10 mg/ml streptomycin sulfate and 2 mg/ml polybrene are exposed to HIV (HTLV-IIIB) and different

concentrations of the test compounds. The plates are incubated at 37°C in 5 % CO₂ for 6-7 days. The contents in each well is then homogenized with a pipette and transferred to a centrifuge tube. After centrifugation for 10 min at 1500 rpm the supernatant is removed and the cell pellet is analyzed by fixing in methanol on glass plates. Human HIV positive serum diluted 1:80 or 1:160 is added and incubated for 30 min at 37°C. The plate is then washed with phosphate-buffered saline (PBS) containing Ca²⁺ and Mg²⁺. Sheep antihuman conjugate (FITC) is added and after a new incubation the plate is again washed with PBS. Contrast staining is done with Evans blue and after drying the frequency of HIV antigen containing cells is determined in a microscope. The test result is shown in Table 1.

Table 1

Concentration (mM) for 50 % inhibition (IC₅₀) of human immuno deficiency virus multiplication in cell culture

Compound	IC ₅₀ μM
1-[2',3'-Dideoxy-3'-C-(hydroxymethyl)-β-D-erythro-pentafuranosyl]cytosine	0.01
1-[2',3'-Dideoxy-3'-C-(hydroxymethyl)-α-D-erythro-pentafuranosyl]cytosine	5
1-[2',3'-Dideoxy-3'-C-(hydroxymethyl)-β-D-erythro-pentafuranosyl]thymine	5
1-[2',3'-Dideoxy-3'-C-(hydroxymethyl)-α-D-erythro-pentafuranosyl]thymine	10
9-[2',3'-Dideoxy-3'-C-(hydroxymethyl)-α-D-erythro-pentafuranosyl]adenine	10

Table 1 shows that the tested compounds are active inhibitors of HIV virus multiplication.

T st II. Cellular toxicity

H9 cells, 2×10^7 cells per plate, are incubated in RPMI-1640 medium containing 10 % fetal calf serum, 70 mg/l penicillin, 100 mg/l streptomycin and 10 mM hepes, in absence or presence of test compounds. The number of cells per plate is determined after 48 h. Cells incubated in the absence of test compounds then underwent two cell division cycles.

F5000 cells, which are human embryo cells, 1×10^5 cells per plate, are incubated in Eagle's minimal essential medium, supplemented with Earle's salts, non-essential amino acids, 10 % fetal calf serum, 10 mM hepes, 70 mg/l penicillin and 100 mg/l streptomycin, in absence or presence of test compounds. The number of cells per plate is determined after 48 h. Cells incubated in the absence of test compounds underwent one cell division cycle. The results are given as % inhibition of cell multiplication and are given in Table 2.


Table 2. Cellular toxicity on H9 cells

Compound	% Inhibition (H9)
1-[2',3'-Dideoxy-3'-(hydroxymethyl)- β -D- -erythro-pentofuranosyl]cytosine (1 mM)	50

Table 2 shows that the concentration at which the compound exhibit toxicity exceed the concentration needed for 50 % inhibition of HIV multiplication as given in Table 1.

CLAIMS



1. A compound of the formula



1A

wherein X is O, S, SO, SO₂, CH₂; R¹ is OH, O-PO(OH)₂, O-PO(OH)-O-PO(OH)₂, O-PO(OH)-O-PO(OH)-O-PO(OH)₂ or (CH₂)_nOCH₂PO(OH)₂ wherein n is 0-2;

R² is H and R³ is CH₃, CH₂OH, CH₂OCH₃, CH₂SH, CH₂F or CH₂N₃; or R³ is H and R² is CH₃, CH₂OH, CH₂OCH₃, CH₂SH, CH₂F or CH₂N₃;



Y is OH, NH₂ and R⁵ is CH=CH₂, C≡CH, CH=CH-CH₃, C≡C-CH₃, thien-2-yl, thien-3-yl, H, CH₃, C₂H₅, CH₂CH₂CH₃ or CH(CH₃)₂;


R⁶ and R⁷ are the same or different and are H, F, Cl, OH, NH₂ or SH;

in the form of a mixture of α- and β-anomers or in the form of an α- or β-anomer; and pharmaceutically acceptable salts thereof, with the provisos:

a) In the combination wherein X is O, S; R² is H and R³ is


CH_2OH ; Y is OH, NH_2 ; R^5 is $\text{CH}=\text{CH}_2$, $\text{C}\equiv\text{CH}$, $\text{CH}=\text{CHCH}_3$, H, CH_3 , C_2H_5 , $\text{CH}_2\text{CH}_2\text{CH}_3$, $\text{CH}(\text{CH}_3)_2$; then the claimed compounds of the formula 1A only are these in the form of the β -anomer.

b) In the combination wherein X is CH_2 ; R^2 is H and R^3 is CH_2OH ; the claimed compounds of the formula 1A are those wherein R^4 is



and R^6 and R^7 are the same or different and are H, Cl, OH, NH_2 or SH.



2. A compound of the formula



1B

wherein X is O, S, SO, SO_2 , CH_2 ; R^1 is OH, $\text{O}-\text{PO}(\text{OH})_2$, $\text{O}-\text{PO}(\text{OH})-\text{O}-\text{PO}(\text{OH})_2$, $\text{O}-\text{PO}(\text{OH})-\text{O}-\text{PO}(\text{OH})-\text{O}-\text{PO}(\text{OH})_2$ or $(\text{CH}_2)_n\text{OCH}_2\text{PO}(\text{OH})_2$ wherein n is 0-2;

R^2 is H and R^3 is CH_3 , CH_2OH , CH_2OCH_3 , CH_2SH , CH_2F or CH_2N_3 ; or R^3 is H and R^2 is CH_3 , CH_2OH , CH_2OCH_3 , CH_2SH , CH_2F or CH_2N_3 ;



Y is OH, NH_2 and R^5 is $\text{CH}=\text{CH}_2$, $\text{C}\equiv\text{CH}$, $\text{CH}=\text{CH}-\text{CH}_3$, $\text{C}\equiv\text{C}-\text{CH}_3$, thien-2-yl, thien-3-yl, H, CH_3 , C_2H_5 , $\text{CH}_2\text{CH}_2\text{CH}_3$ or

$\text{CH}(\text{CH}_3)_2$;

R^6 and R^7 are the same or different and are H, F, Cl, OH, NH_2 or SH;

in the form of a mixture of α - and β -anomers or in the form of an α - or β -anomer; and pharmaceutically acceptable salts thereof.

3. A compound according to any of claims 1 - 2 wherein X is O.
4. A compound according to any of claims 1 - 2 wherein X is S, SO or SO_2 .
5. A compound according to any of claims 1 - 2 wherein X is CH_2 .
6. A compound according to any of claims 1 - 5 wherein R^1 is OH; R^2 is H and R^3 is CH_2OH ; R^3 is H and R^2 is CH_2OH .
7. A compound according to any of claims 1-5 wherein R^1 is OH; R^2 is H and R^3 is CH_3 , CH_2SH , CH_2OCH_3 , CH_2F , CH_2N_3 ; R^3 is H and R^2 is CH_3 , CH_2SH , CH_2OCH_3 , CH_2F , CH_2N_3 .
8. A compound according to any of claims 1-5 wherein R^1 is $(\text{CH}_2)_n\text{OCH}_2\text{PO}(\text{OH})_2$ and n is 0 - 2.
9. A compound according to any of claims 1-8 wherein X is OH, NH_2 and R^5 is H, CH_3 , $\text{CH}=\text{CH}_2$, $\text{C}\equiv\text{CH}$ or $\text{CH}=\text{CH}-\text{CH}_3$.
10. A compound according to any of claims 1-8 wherein R^6 is NH_2 when R^7 is H, OH, SH or NH_2 .
11. A compound according to any of claims 1-8 wherein R^6 is H, F or Cl when R^7 is OH, SH or NH_2 .
12. A compound according to any of claims 1-8 wherein R^6 and R^7 are OH.


13. A compound according to any of claims 1-12 in the form of an α -anomer.
14. A compound according to any of claims 1-12 in the form of a β -anomer.
15. A compound of the formula 1A and 1B according to any of claims 1-14 for use in therapy.
16. A pharmaceutical composition comprising as an active ingredient a compound of the formulas 1A and 1B according to any of claims 1-14 and a pharmaceutically acceptable carrier, including liposomes.
17. A method for treatment of virus infections in an animal or human host in need of treatment, comprising administering an effective amount of a compound of the formulas 1A and 1B as defined in any of claims 1-14.
18. A method according to claim 17 for treatment of infections caused by viruses requiring reverse transcriptase for replication, including human immuno deficiency viruses and hepatitis B virus.
19. A method according to claim 17 for treatment of infections caused by herpes viruses.
20. A method according to claim 17 for treatment of infections caused by parasites.
21. Use of a compound of the formula 1A and 1B according to any of claims 1-14 for the manufacture of a medicament for treatment of the acquired immuno deficiency syndrome and infections caused by viruses requiring reverse transcriptase for replication.
22. Use according to claim 21 for the treatment of infections caused by HIV-viruses.
23. Use according to claim 21 for the treatment of infections

caused by hepatitis B virus.


24. Use according to claim 21 for the treatment of infections caused by herpes viruses.

25. Use according to claim 21 for the treatment of infections caused by parasites.

26. A process for preparation of a compound of the formula




wherein X, R¹, R², R³ and R⁴ are as defined in claim 1, by condensing a glycoside as comprised in the formula to the N-1 position of a pyrimidine derivative or to the N-9 position of a purine derivative




wherein Z is Cl, Br, J, acyloxy or alkoxy. R^{1'}, R^{2'} and R^{3'} are R¹, R² and R³ respectively as defined above or with the proviso that when R¹ or R² is OH then O must have a protecting group, R^{4'} is R⁴ as defined above, having a silyl, acyl or alkyl protecting group.

27. A process for the preparation of a compound of the formula




wherein X, R¹, R² and R³ are as defined in claim 1, by condensing a glycoside as comprised in the formula to the N-1 position of a pyrimidine derivative or to the N-9 position of a purine derivative



wherein Z is Cl, Br, J, acyloxy or alkoxy. R^{1'}, R^{2'} and R^{3'} are R¹, R² and R³ respectively as defined above or with the proviso that when R¹ or R² is OH then O must have a protecting group, R^{4'} is R⁴ as defined above, having a silyl, acyl or alkyl protecting group.

28. A process for preparation of a compound of the formula



wherein X, R¹, R² and R³ are as defined in claim 1 and Z is Cl, Br, J, acyloxy or alkoxy, by reacting a protected butan-1,4-diol-2,3 epoxide with a nucleophile containing 3 or 4 carbon atoms with a double bond, followed by transforming the double bond and ring closure.

INTERNATIONAL SEARCH REPORT

International Application No PCT/SE 91/00653

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁵ According to International Patent Classification (IPC) or to both National Classification and IPC IPC5: C 07 H 19/06, 19/067, 19/073, 19/16, 19/167, 19/73																	
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Minimum Documentation Searched⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 30%; border-bottom: 1px solid black;">Classification System</th> <th style="border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="height: 40px; vertical-align: bottom; border-right: 1px solid black;">IPC5</td> <td>C 07 H</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Documentation Searched other than Minimum Documentation to the extent that such Documents are included in Fields Searched⁸</div>			Classification System	Classification Symbols	IPC5	C 07 H											
Classification System	Classification Symbols																
IPC5	C 07 H																
SE,DK,FI,NO classes as above																	
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹ <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%; border-bottom: 1px solid black;">Category¹⁰</th> <th style="border-bottom: 1px solid black;">Citation of Document,¹¹ with indication, where appropriate, of the relevant passages¹²</th> <th style="border-bottom: 1px solid black;">Relevant to Claim No.¹³</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; vertical-align: top;">X</td> <td>WO, A1, 8808001 (AKTIEBOLAGET ASTRA) 20 October 1988, see page 8 <div style="text-align: center;">--</div></td> <td style="text-align: center; vertical-align: top;">1-16,21-28</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">X</td> <td>EP, A2, 0391411 (BRISTOL-MYERS SQUIBB COMPANY) 10 October 1990, see example 36 <div style="text-align: center;">--</div></td> <td style="text-align: center; vertical-align: top;">1-16,21-28</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">A</td> <td>EP, A2, 0357571 (MEDIVIR AKTIEBOLAG) 7 March 1990, see the whole document <div style="text-align: center;">--</div></td> <td style="text-align: center; vertical-align: top;">1-16,21-28</td> </tr> <tr> <td style="text-align: center; vertical-align: top;">A</td> <td>EP, A1, 0322384 (MEDIVIR AKTIEBOLAG) 28 June 1989, see the whole document <div style="text-align: center;">--</div></td> <td style="text-align: center; vertical-align: top;">1-16,21-28</td> </tr> </tbody> </table>			Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X	WO, A1, 8808001 (AKTIEBOLAGET ASTRA) 20 October 1988, see page 8 <div style="text-align: center;">--</div>	1-16,21-28	X	EP, A2, 0391411 (BRISTOL-MYERS SQUIBB COMPANY) 10 October 1990, see example 36 <div style="text-align: center;">--</div>	1-16,21-28	A	EP, A2, 0357571 (MEDIVIR AKTIEBOLAG) 7 March 1990, see the whole document <div style="text-align: center;">--</div>	1-16,21-28	A	EP, A1, 0322384 (MEDIVIR AKTIEBOLAG) 28 June 1989, see the whole document <div style="text-align: center;">--</div>	1-16,21-28
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³															
X	WO, A1, 8808001 (AKTIEBOLAGET ASTRA) 20 October 1988, see page 8 <div style="text-align: center;">--</div>	1-16,21-28															
X	EP, A2, 0391411 (BRISTOL-MYERS SQUIBB COMPANY) 10 October 1990, see example 36 <div style="text-align: center;">--</div>	1-16,21-28															
A	EP, A2, 0357571 (MEDIVIR AKTIEBOLAG) 7 March 1990, see the whole document <div style="text-align: center;">--</div>	1-16,21-28															
A	EP, A1, 0322384 (MEDIVIR AKTIEBOLAG) 28 June 1989, see the whole document <div style="text-align: center;">--</div>	1-16,21-28															
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents:</p> <p>^A document defining the general state of the art which is not considered to be of particular relevance</p> <p>^E earlier document but published on or after the international filing date</p> <p>^L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>^O document referring to an oral disclosure, use, exhibition or other means</p> <p>^P document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>^T later document published after the international filing date or priority date and not in conflict with the application but cited to understate the principle or theory underlying the invention</p> <p>^X document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>^Y document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>^A document member of the same patent family</p> </div> </div>																	
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black;">Date of the Actual Completion of the International Search</td> <td style="width: 50%; border-bottom: 1px solid black;">Date of Mailing of this International Search Report</td> </tr> <tr> <td style="text-align: center; height: 30px;">7th January 1992</td> <td style="text-align: center; height: 30px;">1992 -01- 13</td> </tr> <tr> <td style="border-bottom: 1px solid black;">International Searching Authority</td> <td style="border-bottom: 1px solid black;">Signature of Authorized Officer</td> </tr> <tr> <td style="text-align: center; height: 40px;">SWEDISH PATENT OFFICE</td> <td style="text-align: center; height: 40px;"> Eva Johansson </td> </tr> </table>			Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	7th January 1992	1992 -01- 13	International Searching Authority	Signature of Authorized Officer	SWEDISH PATENT OFFICE	 Eva Johansson							
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report																
7th January 1992	1992 -01- 13																
International Searching Authority	Signature of Authorized Officer																
SWEDISH PATENT OFFICE	 Eva Johansson																

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
A	EP, A2, 0286825 (MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. ET AL.) 19 October 1988, see the whole document --	1-16,21-28
A	US, A, 3817982 (JULIAN P.H. VERHEYDEN ET AL.) 18 June 1974, see the whole document --	1-16,21-28
A	Journal of Medicinal Chemistry, Vol. 22, No. 5, 1979, Edward M. Acton et al: "Improved antitumor effects in 3'-branched homologues of 2'-deoxythioguanosine. Synthesis and evaluation of thioguanine nucleosides of 2,3-dideoxy-3-(hydroxymethyl)-D-erythro-pentofuranose", see page 518 - page 525 -- -----	1-16,21-28

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers 17-20 because they relate to subject matter not required to be searched by this Authority, namely:

See PCT Rule 39.1(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.

2. ☐ Claim numbers..... because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers..... because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING²

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims. It is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. PCT/SE 91/00653

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the Swedish Patent Office EDP file on 31/10/91. The Swedish Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A1- 8808001	88-10-20	AU-B- 614082	91-08-22
		AU-D- 1689988	88-11-04
		EP-A- 0309560	89-04-05
EP-A2- 0391411	90-10-10	AU-D- 5256090	90-10-11
		CA-A- 2013874	90-10-06
		JP-A- 2290895	90-11-30
EP-A2- 0357571	90-03-07	AU-D- 3750489	90-01-05
		WO-A- 89/12061	89-12-14
EP-A1- 0322384	89-06-28	AU-D- 2452288	89-05-04
		JP-A- 1151595	89-06-14
EP-A2- 0286825	88-10-19	AU-B- 609099	91-04-26
		AU-D- 1308188	88-09-22
		DE-A- 3708849	88-09-29
		EP-A- 0332626	89-09-20
		JP-T- 2500364	90-02-08
		US-A- 4880782	89-11-14
		WO-A- 88/03804	88-06-02
US-A- 3817982	74-06-18	NONE	